AXT INC Form 10-Q
November 07, 2018 <u>Table of Contents</u>
0
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
for the quarterly period ended September 30, 2018
Or
Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
for the transition period from to
Commission File Number 000-24085

AXT.	INC.
$\Delta \Delta 1$.	mv.

(Exact name of registrant as specified in its charter)

DELAWARE 94-3031310 (State or other jurisdiction of Incorporation or organization) Identification No.)

4281 Technology Drive, Fremont, California 94538

(Address of principal executive offices) (Zip code)

(510) 438-4700

(Registrant's telephone number, including area code)

Indicate by check-mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check-mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check-mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Non-accelerated filer Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check-mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check-mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES NO

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class Outstanding at November 1, 2018

Common Stock, \$0.001 par value 39,537,821

Table of Contents

AXT, INC.

FORM 10-Q

2

TABLE OF CONTENTS

	Page
PART I. FINANCIAL INFORMATION	
Item 1. Financial Statements (unaudited)	
Condensed Consolidated Balance Sheets as of September 30, 2018 and December 31, 2017	3
Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2018 and	<u>l</u> 4
<u>2017</u>	
Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended September	5
30, 2018 and 2017	
Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2018 and 2017	6
Notes To Condensed Consolidated Financial Statements	7
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	27
Item 3. Quantitative and Qualitative Disclosures About Market Risk	44
Item 4. Controls and Procedures	46
PART II. OTHER INFORMATION	
Item 1. Legal Proceedings	47
Item 1A. Risk Factors	47
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	67
Item 3. Defaults upon Senior Securities	67
Item 4. Mine Safety Disclosures	67
Item 5. Other Information	68
Item 6. Exhibits	69
<u>Signatures</u>	71

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements (unaudited)

AXT, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited, in thousands, except per share data)

	Se ₃	ptember 30, 18	ecember 31, 017
ASSETS			
Current assets:			
Cash and cash equivalents	\$	18,035	\$ 44,352
Short-term investments		21,910	20,032
Accounts receivable, net of allowances of \$358 and \$527 as of			
September 30, 2018 and December 31, 2017		23,308	22,778
Inventories		58,717	45,840
Prepaid expenses and other current assets		10,625	7,519
Total current assets		132,595	140,521
Long-term investments		1,906	12,576
Property, plant and equipment, net		74,754	46,530
Other assets		11,194	11,573
Total assets	\$	220,449	\$ 211,200
LIABILITIES AND STOCKHOLDERS' EQUITY			
Current liabilities:			
Accounts payable	\$	12,344	\$ 11,445
Accrued liabilities		12,776	11,149
Bank loan		291	
Total current liabilities		25,411	22,594
Other long-term liabilities		320	289
Total liabilities		25,731	22,883
Commitments and contingencies (Note 12)			
Stockholders' equity:			
Preferred stock Series A, \$0.001 par value; 2,000 shares authorized; 883			
shares issued and outstanding as of September 30, 2018 and			
December 31, 2017 (Liquidation preference of \$6,948 and \$6,819			
as of September 30, 2018 and December 31, 2017)		3,532	3,532
Common stock, \$0.001 par value; 70,000 shares authorized; 39,538 and 39,413 shares issued and outstanding as of September 30, 2018 and		39	39

December 31, 2017		
Additional paid-in capital	233,522	231,679
Accumulated deficit	(44,122)	(54,837)
Accumulated other comprehensive income (loss)	(1,846)	3,407
Total AXT, Inc. stockholders' equity	191,125	183,820
Noncontrolling interests	3,593	4,497
Total stockholders' equity	194,718	188,317
Total liabilities and stockholders' equity	\$ 220,449	\$ 211,200

See accompanying notes to condensed consolidated financial statements.

AXT, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, in thousands, except per share data)

	Three Months Ended September 30,		Nine Month September 3		
	2018	2017	2018	2017	
Revenue	\$ 28,626	\$ 28,168	\$ 80,165	\$ 72,341	
Cost of revenue	18,012	17,035	48,968	47,664	
Gross profit	10,614	11,133	31,197	24,677	
Operating expenses:					
Selling, general and administrative	4,615	4,484	13,824	12,219	
Research and development	1,668	1,410	4,588	3,553	
Total operating expenses	6,283	5,894	18,412	15,772	
Income from operations	4,331	5,239	12,785	8,905	
Interest income, net	133	122	414	334	
Equity in earnings (loss) of unconsolidated joint ventures	6	(266)	(21)	(1,387)	
Other income (expense), net	87	(349)	(179)	(403)	
Income before provision for income taxes	4,557	4,746	12,999	7,449	
Provision for income taxes	410	181	1,111	661	
Net income	4,147	4,565	11,888	6,788	
Less: Net (income) loss attributable to noncontrolling					
interests	(208)	(146)	(1,173)	226	
Net income attributable to AXT, Inc.	\$ 3,939	\$ 4,419	\$ 10,715	\$ 7,014	
Net income attributable to AXT, Inc. per common share:					
Basic	\$ 0.10	\$ 0.11	\$ 0.27	\$ 0.19	
Diluted	\$ 0.10	\$ 0.11	\$ 0.26	\$ 0.18	
Weighted-average number of common shares outstanding:					
Basic	39,008	38,499	39,000	36,999	
Diluted	40,331	40,095	40,320	38,469	

See accompanying notes to condensed consolidated financial statements.

AXT, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited, in thousands)

	Three Months Ended September 30,		Nine Month September 3	
	2018	2017	2017 2018	
Net income	\$ 4,147	\$ 4,565	\$ 11,888	\$ 6,788
Other comprehensive (loss) income, net of tax:				
Change in foreign currency translation (loss) gain, net of tax	(3,316)	1,135	(5,518)	2,457
Change in unrealized gain (loss) on available-for-sale				
investments, net of tax	59	27	(18)	(98)
Total other comprehensive (loss) income, net of tax	(3,257)	1,162	(5,536)	2,359
Comprehensive income	890	5,727	6,352	9,147
Less: Comprehensive loss (income) attributable to				
noncontrolling interests	31	(326)	(890)	(111)
Comprehensive income attributable to AXT, Inc.	\$ 921	\$ 5,401	\$ 5,462	\$ 9,036

See accompanying notes to condensed consolidated financial statements.

AXT, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited, in thousands)

	Nine Months September 30	
	2018	2017
Cash flows from operating activities:		
Net income	\$ 11,888	\$ 6,788
Adjustments to reconcile net income to net cash (used in) provided by operating activities:		
Depreciation and amortization	3,445	3,361
Amortization of marketable securities premium	120	124
Impairment charge on equity investee		313
Stock-based compensation	1,392	961
Realized gain on sale of available-for-sale securities		(77)
Loss on disposal of equipment	25	_
Loss from equity method investments, net	21	1,074
Changes in operating assets and liabilities:		
Accounts receivable	(917)	(6,206)
Inventories	(14,637)	(66)
Prepaid expenses and other current assets	(3,492)	(587)
Other assets	48	64
Accounts payable	1,283	2,589
Accrued liabilities	745 *	(107) *
Other long-term liabilities, including royalties	(148)	(241)
Net cash (used in) provided by operating activities	(227)	7,990
Cash flows from investing activities:		
Purchases of property, plant and equipment	(34,289)	(16,557)
Proceeds from sale of equipment	11	
Purchases of available-for-sale securities	(9,936)	(26,093)
Proceeds from sales and maturities of available-for-sale securities	18,590	13,310
Repayment of related party notes receivable		108
Net cash used in investing activities	(25,624)	(29,232)
Cash flows from financing activities:	, ,	,
Proceeds from issuance of common stock and options exercised, net of issuance		
costs	264	33,384
Considerations paid in cash to repurchase subsidiary shares from noncontrolling		•
interests	(415)	_
Proceeds from short-term loan	291	_
Dividends paid by joint ventures to their minority shareholders		(465)
Net cash provided by financing activities	140	32,919
Effect of exchange rate changes on cash and cash equivalents	(606)	249
Net increase (decrease) in cash and cash equivalents	(26,317)	11,926
· · · · · · · · · · · · · · · · · · ·	· - / /	>

Cash and cash equivalents at the beginning of the period	44,352	36,152
Cash and cash equivalents at the end of the period	\$ 18,035	\$ 48,078
Supplemental disclosure of non-cash flow information:		
Consideration payable to repurchase subsidiary shares from noncontrolling interests,		
included in accrued liabilities	\$ 1,192	_
Reduction of noncontrolling interests in excess of total consideration paid and		
payable in connection with the repurchase of subsidiaries shares from noncontrolling		
interests	\$ 187	_

^{*} Dividend accrued but not paid by one of our consolidated subsidiaries of \$505 and \$521 was included in accrued liabilities as of September 30, 2018 and 2017, respectively.

See accompanying notes to condensed consolidated financial statements.

— 1	1	c	~
Tah)le	ot	Contents

AXT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1. Basis of Presentation

The accompanying condensed consolidated financial statements of AXT, Inc. ("AXT," the "Company," "we," "us," and "our" refer to AXT, Inc. and all of its consolidated subsidiaries) are unaudited, and have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, this interim quarterly financial report does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of our management, the unaudited condensed consolidated financial statements reflect all adjustments, consisting only of normal recurring adjustments, considered necessary to present fairly the financial position, results of operations and cash flows of AXT and our consolidated subsidiaries for all periods presented.

Certain reclassifications have been made to prior periods' financial statements to conform to the current period presentation. These reclassifications did not result in any change in previously reported net income or total assets.

Our management has made a number of estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities to prepare these condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America. Actual results could differ materially from those estimates.

The results of operations for the three and nine months ended September 30, 2018 are not necessarily indicative of the results to be expected in the future or for the full fiscal year. It is recommended that these condensed consolidated financial statements be read in conjunction with our consolidated financial statements and the notes thereto included in our 2017 Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 9, 2018 and our Quarterly Reports on Form 10-Q for the three months ended March 31, 2018 and June 30, 2018 filed with the SEC on May 4, 2018 and August 7, 2018, respectively.

The condensed consolidated financial statements include the accounts of AXT, our wholly-owned subsidiaries, Beijing Tongmei Xtal Technology Co., Ltd., Baoding Tongmei Xtal Technology Co., Ltd. and Chaoyang Tongmei Xtal Technology Co., and our majority-owned, or significantly controlled subsidiaries, Beijing JiYa Semiconductor Material Co., Ltd., Nanjing JinMei Gallium Co., Ltd. and Beijing BoYu Semiconductor Vessel Craftwork Technology Co., Ltd. All significant inter company accounts and transactions have been eliminated. Investments in business entities in which we do not have controlling interests, but have the ability to exercise significant influence over operating and financial policies (generally 20-50% ownership), are accounted for by the equity method. We have seven companies accounted for by the equity method. For subsidiaries that we consolidate, we reflect the portion we do not own as noncontrolling interests on our condensed consolidated balance sheets in stockholders' equity and in our condensed consolidated statements of operations.

Note 2. Investments and Fair Value Measurements

Our cash and cash equivalents consist of cash and instruments with original maturities of less than three months. Our investments consist of instruments with original maturities of more than three months. As of September 30, 2018 and December 31, 2017, our cash, cash equivalents and investments are classified as follows (in thousands):

	September 30, 2018				December 31, 2017			
		Gross	Gross			Gross	Gross	
	Amortized	Unreali	z & hrealized	Fair	Amortized	Unreali	z e chrealize	ed Fair
	Cost	Gain	(Loss)	Value	Cost	Gain	(Loss)	Value
Classified as:								
Cash	\$ 16,288	\$ —	\$ —	\$ 16,288	\$ 43,610	\$ —	\$ —	\$ 43,610
Cash equivalents:								
Certificates of								
deposit 1	1,747			1,747	742			742
Total cash and cash								
equivalents	18,035	_		18,035	44,352			44,352
Investments								
(available-for-sale):								
Certificates of	- 1.50							
deposit 2	5,468		(31)	5,437	7,099		(24)	7,075
Corporate bonds	18,459		(80)	18,379	25,602		(69)	25,533
Total investments	23,927		(111)	23,816	32,701		(93)	32,608
Total cash, cash								
equivalents and	* 44 0 62			.	* 0.50	Φ.	d (0.0)	
investments	\$ 41,962	\$ —	\$ (111)	\$ 41,851	\$ 77,053	\$ —	\$ (93)	\$ 76,960
Contractual								
maturities on								
investments:	Φ 22 007			ф. 21 010	Φ 20 056			Φ 20 022
Due within 1 year 3	\$ 22,007			\$ 21,910	\$ 20,056			\$ 20,032
Due after 1 through	1.000			1.006	10 645			10.556
5 years 4	1,920			1,906	12,645			12,576
	\$ 23,927			\$ 23,816	\$ 32,701			\$ 32,608

^{1.} Certificates of deposit with original maturities of less than three months

^{2.} Certificates of deposit with original maturities of more than three months.

^{3.} Classified as "Short-term investments" in our condensed consolidated balance sheets.

^{4.} Classified as "Long-term investments" in our condensed consolidated balance sheets.

We manage our investments as a single portfolio of highly marketable securities that is intended to be available to meet our current cash requirements. Certificates of deposit and corporate bonds are typically held until maturity. Corporate equity securities have no maturity and may be sold at any time.

We previously held corporate equity securities consisting of common stock of GCS Holdings, Inc. ("GHI") (previously Global Communication Semiconductors, Inc.), a Taiwan publicly-traded company. We began classifying GHI as an available-for-sale security in the second quarter of 2015 when we determined that there was sufficient trading volume in the exchange for the stock to be deemed readily marketable. During the three months ended March 31, 2017, we sold the remainder of our GHI stock. During the nine months ended September 30, 2017, our cash proceeds from sales of GHI stock were \$125,000. Our cost was \$48,000 and our gross realized gain from sales of GHI stock was \$77,000. There were no GHI transactions in the three and nine months ended September 30, 2018.

The gross unrealized losses related to our portfolio of available-for-sale securities were primarily due to changes in interest rates and market and credit conditions of the underlying securities. We have determined that the gross unrealized losses on our available-for-sale securities as of September 30, 2018 are temporary in nature. We periodically review our investment portfolio to identify and evaluate investments that have indications of possible impairment. Factors considered in determining whether a loss is temporary include the magnitude of the decline in market value, the length of time the market value has been below cost (or adjusted cost), credit quality, and our ability and intent to hold the securities for a period of time sufficient to allow for any anticipated recovery in market value.

A portion of our investments would generate a loss if we sold them on September 30, 2018. The following table summarizes the fair value and gross unrealized losses related to available-for-sale securities, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position as of September 30, 2018 (in thousands):

	In Loss Position < 12 months		In Loss Position > 12 months		Total In Loss Position	
		Gross		Gross		Gross
	Fair	Unrealized	Fair	Unrealized	Fair	Unrealized
As of September 30, 2018	Value	(Losses)	Value	(Losses)	Value	(Losses)
Investments:						
Certificates of deposit	\$ 2,625	\$ (15)	\$ 2,794	\$ (16)	\$ 5,419	\$ (31)
Corporate bonds	11,155	(56)	7,224	(24)	18,379	(80)
Total in loss position	\$ 13,780	\$ (71)	\$ 10,018	\$ (40)	\$ 23,798	\$ (111)

The following table summarizes the fair value and gross unrealized losses related to available-for-sale securities, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position as of December 31, 2017 (in thousands):

		In Loss Position < 12 months			In Loss Position > 12 months			Total In Loss Position				
			Gı	ross			Gr	ross			G	ross
	Fa	ir	Uı	nrealized	Fa	ir	Ur	realized	Fa	ir	U	nrealized
As of December 31, 2017	Va	alue	(L	oss)	Va	alue	(L	oss)	Va	alue	(L	oss)
Investments:												
Certificates of deposit	\$	3,994	\$	(16)	\$	2,342	\$	(8)	\$	6,336	\$	(24)
Corporate bonds		25,533		(69)		_				25,533		(69)
Total in loss position	\$	29,527	\$	(85)	\$	2,342	\$	(8)	\$	31,869	\$	(93)

Investments in Privately-held Companies

We have made strategic investments in private companies located in China in order to gain access at a competitive cost to raw materials that are critical to our substrate business (see Note 7). The investment balances for all of these companies, including minority investments indirectly in privately-held companies made by our consolidated subsidiaries, are accounted for under the equity method and included in "Other assets" in the condensed consolidated balance sheets and totaled \$9.5 million and \$9.8 million as of September 30, 2018 and December 31, 2017, respectively. As of September 30, 2018, there were seven companies accounted for under the equity method. There were no impairment charges in the three and nine months ended September 30, 2018. There were no impairment charges in the three months ended September 30, 2017 include an

impairment charge of \$313,000 for one of the joint ventures that produces gallium. During the first quarter of 2017, management determined that it was unlikely that this company would recover from the difficult pricing environment and we wrote the investment down to zero.

Fair Value Measurements

We invest primarily in money market accounts, certificates of deposits, corporate bonds and notes, and government securities. Accounting Standards Codification ("ASC") Topic 820, Fair Value Measurements and Disclosures ("ASC 820"), establishes three levels of inputs that may be used to measure fair value. Level 1 instrument valuations are obtained from real-time quotes for transactions in active exchange markets of the asset or identical assets. Level 2 instrument valuations are obtained from readily-available, observable pricing sources for comparable instruments. Level 3 instrument valuations are obtained from unobservable inputs in which there is little or no market data, which require us to develop our own assumptions. On a recurring basis, we measure certain financial assets and liabilities at fair value, primarily consisting of our short-term and long-term investments.

The type of instrument valued based on quoted market prices in active markets include our money market funds, which are generally classified within Level 1 of the fair value hierarchy. Other than corporate equity securities

Table of Contents

which are based on quoted market prices and classified as Level 1, we classify our available-for-sale securities including certificates of deposit and corporate bonds as having Level 2 inputs. The valuation techniques used to measure the fair value of these financial instruments having Level 2 inputs were derived from bank statements, quoted market prices, broker or dealer statements or quotations, or alternative pricing sources with reasonable levels of price transparency.

We place short-term foreign currency hedges that are intended to offset the potential cash exposure related to fluctuations in the exchange rate between the United States dollar and Japanese Yen. We measure the fair value of these foreign currency hedges at each month end and quarter end using current exchange rates and in accordance with generally accepted accounting principles. At quarter end any foreign currency hedges not settled are netted in "Accrued liabilities" on the condensed consolidated balance sheet and classified as Level 3 assets and liabilities. As of September 30, 2018, the net change in fair value from the placement of the hedge to settlement at each month end during the quarter had a de minimis impact to the consolidated results.

There were no changes in valuation techniques or related inputs in the three and nine months ended September 30, 2018. There have been no transfers between fair value measurements levels during the three and nine months ended September 30, 2018.

The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis in accordance with ASC 820 as of September 30, 2018 (in thousands):

	 llance as of ptember 30, 2018	Active	Prices in Markets of al Assets 1)	Oł	gnificant Other oservable Inputs evel 2)	Signif Unobs Inputs (Leve	servable
Assets:							
Cash equivalents and							
investments:							
Certificates of deposit	\$ 7,184	\$	_	\$	7,184	\$	
Corporate bonds	18,379				18,379		
Total	\$ 25,563	\$	_	\$	25,563	\$	

The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis in accordance with ASC 820 as of December 31, 2017 (in thousands):

Quoted Prices in

Significant

Edgar Filing: AXT INC - Form 10-Q

	 lance as of ecember 31, 2017	Markets of al Assets 1)	Ob	gnificant Other eservable Inputs evel 2)	Unobs Inputs (Leve	
Assets:						
Cash equivalents and						
investments:						
Certificates of deposit	\$ 7,817	\$ _	\$	7,817	\$	
Corporate bonds	25,533	_		25,533		
Total	\$ 33,350	\$ _	\$	33,350	\$	

Items Measured at Fair Value on a Nonrecurring Basis

Certain assets that are subject to nonrecurring fair value measurements are not included in the table above. These assets include investments in privately-held companies accounted for by the equity or cost method (See Note 7). There were no impairment charges in the three and nine months ended September 30, 2018. There were no impairment charges in the three months ended September 30, 2017. The nine months ended September 30, 2017 include an impairment charge of \$313,000 for one of the joint ventures that produces gallium. During the first quarter of 2017, management determined that it was unlikely that this company would recover from the difficult pricing environment and we had written the investment down to zero. Except as mentioned, we did not record other-than-temporary impairment charges for the remainder of these investments during the three and nine months ended September 30, 2018 and 2017.

Note 3. Inventories

The components of inventories are summarized below (in thousands):

	September 30, 2018		December 3 2017	
Inventories:				
Raw materials	\$	29,750	\$	23,554
Work in process		26,055		20,135
Finished goods		2,912		2,151
	\$	58.717	\$	45.840

As of September 30, 2018 and December 31, 2017, carrying values of inventories were net of inventory reserves of \$14.4 million and \$13.3 million, respectively, for excess and obsolete inventory and \$40,000 and \$291,000, respectively, for lower of cost or net realizable value reserves.

Note 4. Property, Plant and Equipment, Net

The components of our property, plant and equipment are summarized below (in thousands):

	September 30 2018	December 31, 2017
Property, plant and equipment:		
Machinery and equipment, at cost	\$ 47,875	\$ 44,549
Less: accumulated depreciation and amortization	(41,034)	(40,845)
Building, at cost	39,374	32,461
Less: accumulated depreciation and amortization	(11,792)	(11,501)
Leasehold improvements, at cost	5,384	5,539
Less: accumulated depreciation and amortization	(4,411)	(4,288)
Construction in progress	39,358	20,615
	\$ 74,754	\$ 46,530

As of September 30, 2018, the balance of construction in progress was \$39.4 million, of which \$24.9 million was related to our buildings in our new Dingxing and Chaoyang locations, \$5.2 million was for manufacturing equipment purchases and \$9.3 million was from our construction in progress for our other consolidated subsidiaries. As of

December 31, 2017, the balance of construction in progress was \$20.6 million, of which, \$14.8 million was for our buildings in our new Dingxing location, \$3.6 million was for manufacturing equipment purchases not yet placed in service, and \$2.2 million was for our construction in progress at our other consolidated subsidiaries.

Note 5. Accrued Liabilities

The components of accrued liabilities are summarized below (in thousands):

	Se ₂	ptember 30,		ecember 31,
D C 1 . 1 !! ! 1 . 11	20		20	
Preferred stock dividends payable		2,901		2,901
Accrued compensation and related charges		2,570		3,205
Payable in connection with repurchase of subsidiaries shares		1,192		
Advance from customers		648		924
Accrued professional services		618		583
Dividends payable by consolidated joint ventures		505		533
Other tax payable		352		395
Accrued income taxes		260		270
Accrued product warranty		228		133
Other personnel related costs		227		230
Current portion of royalty payments		144		575
Accrual for sales refund liabilities		37		
Other accrued liabilities		3,094		1,400
	\$	12,776	\$	11,149

Note 6. Related Party Transactions

In August 2011, our consolidated joint venture, Beijing JiYa Semiconductor Material Co., Ltd. ("JiYa"), entered into a non-interest bearing note agreement in the amount of \$1.6 million for a loan to one of its equity investment entities. The original term of the loan was for two years and ten months with three periodic principal payments required. After various amendments to the terms of the note, in December 2013, the parties agreed to delay all principal repayment until December 2017. In December 2016, we determined that this receivable was in substance an investment and began re-classifying this long term loan from "Related party notes receivable – long-term" to "Other assets" in our consolidated balance sheets. As of September 30, 2018 and December 31, 2017, we included \$1.1 million and \$1.2 million in "Other assets" in our condensed consolidated balance sheets, respectively.

JiYa also purchases raw materials from one of its equity investment entities for production in the ordinary course of business. The general manager of JiYa has a family member who has a 10% ownership position in this equity investment entity. As of September 30, 2018 and December 31, 2017, amounts payable of \$1.9 million and \$2.1 million were included in "Accounts payable" in our condensed consolidated balance sheets, respectively.

JiYa also sells raw materials to one of its equity investment entities for production in the ordinary course of business. As of September 30, 2018 and December 31, 2017, amounts receivable of \$316,000 and \$334,000, respectively, were included in "Accounts receivable" in our condensed consolidated balance sheets. During the three months ended December 31, 2016, we deemed the collection of the outstanding amount to be improbable and established an allowance in full. There have since been no additional sales made on credit to the customer and, as of September 30, 2018, the existing outstanding amount continues to be fully reserved.

Beginning in 2012, our consolidated joint venture, Nanjing JinMei Gallium Co., Ltd. ("JinMei"), is contractually obligated under an agency sales agreement to sell raw material on behalf of its equity investment entity. JinMei bills the customers and remits the receipts, net of its portions of sales commission, to this equity investment entity. For the three months ended September 30, 2018 and 2017, JinMei has recorded \$20,000 and \$2,000 income from agency sales, respectively. For the nine months ended September 30, 2018 and 2017, JinMei has recorded \$21,000 and \$3,000 income from agency sales, respectively, which were included in "Other (expense) income, net" in the condensed consolidated statements of operations.

Table of Contents

In March 2012, our wholly-owned subsidiary, Beijing Tongmei Xtal Technology Co., Ltd. ("Tongmei"), entered into an operating lease for the land it owns with our consolidated joint venture, Beijing BoYu Semiconductor Vessel Craftwork Technology Co., Ltd. ("BoYu"). The lease agreement for the land of approximately 22,081 square feet commenced on January 1, 2012 for a term of 10 years with annual lease payments of \$24,000 subject to a 5% increase at each third year anniversary. The annual lease payment is due by January 31st of each year.

Tongmei has paid certain amounts on behalf of Donghai County Dongfang High Purity Electronic Materials Co., Ltd. ("Dongfang"), its equity investment entity, to purchase materials. The original agreement was signed between Tongmei and Dongfang in 2014 and the date of repayment was set as December 31, 2015. In 2015, both parties agreed to delay the date of repayment to December 31, 2017. During 2017, the repayment of the full amount of principal and interest totaling \$114,000 was received by our wholly owned subsidiary.

In April 2014, Tongmei loaned an additional \$46,000 to Dongfang. The loan bears interest at 6.15% per annum and was due on December 31, 2017. During 2017, the repayment of the full amount of principal and interest totaling \$55,000 was received by our wholly owned subsidiary.

Tongmei also purchases raw materials from Dongfang for production in the ordinary course of business. As of September 30, 2018 and December 31, 2017, there were no amounts payable to Dongfang.

Tongmei also purchases raw materials from one of our equity investment entities, Emei Shan Jiamei Materials Co. Ltd. ("Jiamei"), for production in the ordinary course of business. As of September 30, 2018 and December 31, 2017, amounts payable of \$0 and \$370,000, respectively, were included in "Accounts payable" in our condensed consolidated balance sheets.

Tongmei also purchases raw materials from one of our equity investment entities, Xilingol Tongli Germanium Refine Co. Ltd. ("Tongli"), for production in the ordinary course of business. As of September 30, 2018 and December 31, 2017, amounts payable of \$0 and \$219,000, respectively, were included in "Accounts payable" in our condensed consolidated balance sheets.

In July 2017, Tongmei, provided an inter-company loan to JinMei in the amount of \$768,000 in preparation for the acquisition of the land use rights and the construction of a new building. The inter-company loan carries an interest rate of 4.9% per annum and is due in three installments between December 2021 and December 2023. JinMei is in the process of relocating its headquarters and manufacturing operations to an alternative location. Currently, JinMei has identified a site as a possible candidate and the estimated costs for the land use rights acquisition and facility construction are expected to be in the range of \$2 million to \$4 million.

In April 2016, our consolidated joint venture, BoYu, provided a personal loan of \$177,000 to one of its executive employees. This loan is secured by the officer's shares in BoYu. The loan bears interest at 2.75% per annum. Principal and accrued interest are due on March 31, 2019. During the three months ended June 30, 2017, the repayment of the principal and interest totaling \$180,000 was received by our consolidated joint venture. In November 2017, BoYu provided another personal loan of \$318,000 to the same executive employee. The loan bears interest at 2.75% per annum. Principal and accrued interest are due on November 30, 2020. As of September 30, 2018 and December 31, 2017, the balances, including both principal and accrued interest, were \$298,000 and \$307,000, respectively, and included in "Other assets" in our condensed consolidated balance sheets.

On November 2, 2017, our consolidated joint venture, BoYu, raised additional capital in the amount of \$2 million in cash from a third-party investor through the issuance of shares equivalent to 10% ownership of BoYu. This third-party investor is an immediate family member of the owner of one of BoYu's customers. For the three months ended September 30, 2018 and 2017, BoYu has recorded \$37,000 and \$226,000, respectively, in revenue from this customer. For the nine months ended September 30, 2018 and 2017, BoYu has recorded \$1.4 million and \$613,000, respectively, in revenue from this customer. As of September 30, 2018 and December 31, 2017, amounts receivable of \$33,000 and \$635,000, respectively, were included in "Accounts receivable" in our condensed consolidated balance sheets.

Our Related Party Transactions Policy seeks to prohibit all conflicts of interest in transactions between related parties and us, unless they have been approved by our Board of Directors. This policy applies to all of our employees, directors, and our consolidated subsidiaries. Our executive officers retain board seats on the board of directors of the companies in which we have invested in our China joint ventures. See Note 7 for further details.

Note 7. Investments in Privately-Held Companies

We have made strategic investments in private companies located in China in order to gain access at a competitive cost to raw materials that are critical to our substrate business. We have six direct investments. Our consolidated subsidiaries have also made investments in private companies. We have four indirect investments. These companies form part of our overall supply chain.

The six direct investments are summarized below (in thousands):

		Balance as of 30, December 31,	Accounting	Ownership	
Company	2018	2017	Method	Percentag	ge
Beijing JiYa Semiconductor Material Co., Ltd.	\$ 3,331	\$ 3,331	Consolidated	46	%
Nanjing JinMei Gallium Co., Ltd.	592	592	Consolidated	97	%
Beijing BoYu Semiconductor Vessel Craftwork					
Technology Co., Ltd.	1,346	1,346	Consolidated	63	%
	\$ 5,269	\$ 5,269			
Donghai County Dongfang High Purity					
Electronic Materials Co., Ltd.	\$ 1,450	\$ 1,473	Equity	46	%
Xilingol Tongli Germanium Co. Ltd.	2,811	3,190	Equity	25	%
Emeishan Jia Mei High Purity Metals Co., Ltd.	870	915	Equity	25	%
- · ·	\$ 5,131	\$ 5,578			

Our ownership of JiYa is 46%. We continue to consolidate JiYa as we are the founding and largest shareholder, appoint the general manager and controller and have the ability to exercise control in substance over the long-term strategic decisions made. Our Chief Executive Officer is chairman of the JiYa board and we have appointed one other representative, Davis Zhang, to serve on the board. Mr. Zhang was an executive officer of AXT for 27 years. Further, our Chief Financial Officer, Gary Fischer, is on the board of supervisors of JiYa.

Our ownership of JinMei is 97%. Before June 15, 2018, our ownership of JinMei was 83%. On June 15, 2018, we purchased a 12% ownership interest from one of the minority owners for \$1.4 million. The \$1.4 million is scheduled

to be paid in two installments. On June 15, 2018, we paid the first installment of \$163,000. The second installment of \$1.2 million is scheduled to be paid after the completion of the relocation of JinMei's headquarters and manufacturing operations and was included in "Accrued liabilities" in our condensed consolidated balance sheets. As a result, our ownership of JinMei increased from 83% to 95%. In September 2018, we purchased a 2% ownership interest from one of the three remaining minority owners for \$252,000. As a result, our ownership of JinMei increased from 95% to 97%. We continue to consolidate JinMei as we have a controlling financial interest and have majority control of the board. Our Chief Executive Officer is chairman of the JinMei board and we have appointed two other representatives to serve on the board.

Our ownership of BoYu is 63%. On November 2, 2017, BoYu raised additional capital in the amount of \$2 million in cash from a third-party investor through the issuance of shares equivalent to 10% ownership of BoYu. As a result, our ownership of BoYu was diluted from 70% to 63%. We continue to consolidate BoYu as we have a controlling financial interest and have majority control of the board and, accordingly, no gain was recognized as a result of this equity transaction. Our Chief Executive Officer is chairman of the BoYu board and we have appointed two other representatives to serve on the board.

Although we have representation on the board of directors of each of these companies, the daily operations of each of these companies are managed by local management and not by us. Decisions concerning their respective short-

Table of Contents

term strategy and operations, ordinary course of business capital expenditures and sales of finished products, are made by local management with regular guidance and input from us.

During the three months ended September 30, 2018 and 2017, the three consolidated joint ventures, before eliminating inter-company transactions, generated income of \$1.3 million and an income of \$860,000, respectively, of which a gain of \$208,000 and a gain of \$146,000, respectively, were allocated to noncontrolling interests, resulting in an income of \$1.1 million and an income of \$714,000 respectively, to our net income. During the nine months ended September 30, 2018 and 2017, the three consolidated joint ventures generated income of \$4.8 million and income of \$1.1 million, respectively, of which a gain of \$1.2 million and a loss of \$0.2 million respectively, were allocated to noncontrolling interests, resulting in an income of \$3.7 million and an income of \$1.3 million, respectively, to our net income.

For AXT's three direct minority investment entities that are not consolidated, the investment balances are included in "Other assets" in our condensed consolidated balance sheets and totaled \$5.1 million and \$5.6 million as of September 30, 2018 and December 31, 2017, respectively. We own 46% of the ownership interests in one of these companies and 25% in each of the other two companies. These three companies are not considered variable interest entities because:

- · all three companies have sustainable businesses of their own;
- · our voting power is proportionate to our ownership interests;
- · we only recognize our respective share of the losses and/or residual returns generated by the companies if they occur; and
- · we do not have controlling financial interest in, do not maintain operational or management control of, do not control the board of directors of, and are not required to provide additional investment or financial support to any of these companies.

We also maintain four minority investments indirectly in privately-held companies through our consolidated joint ventures. JiYa holds three investments and JinMei holds one investment. These minority investments are accounted for under the equity method in the books of our consolidated joint ventures. As of September 30, 2018 and December 31, 2017, our consolidated joint ventures included these minority investments in "Other assets" in our condensed consolidated balance sheets with a carrying value of \$4.4 million and \$4.3 million, respectively.

There were no impairment charges in the three and nine months ended September 30, 2018. There were no impairment charges in the three months ended September 30, 2017. The nine months ended September 30, 2017 include an impairment charge of \$313,000 for one of the joint ventures that produces gallium. During the first quarter

of 2017, management determined that it is unlikely that this company will recover from the difficult pricing environment and we had wrote the investment down to zero.

AXT's three direct minority investment entities and the three minority investments of JiYa and the one minority investment of JinMei are not consolidated and are accounted for under the equity method. Excluding one fully impaired entity, the equity entities had the following summarized income information (in thousands) for the three and nine months ended September 30, 2018 and 2017.

	Three Mor	nths Ended	Nine Months Ended		
	September 30,		September	30,	
	2018	2017	2018	2017	
Net revenue	\$ 8,017	\$ 4,209	\$ 24,366	\$ 15,571	
Gross profit	\$ 2,141	\$ 177	\$ 5,477	\$ 976	
Operating income (loss)	\$ 631	\$ (1,054)	\$ 767	\$ (2,685)	
Net income (loss)	\$ 315	\$ (1,130)	\$ (422)	\$ (3,653)	

Table of Contents

Our portion, including impairment charges, from these seven minority investment entities that are not consolidated and are accounted for under the equity method was income of \$6,000 and a loss of \$266,000 for the three months ended September 30, 2018 and 2017, respectively. Our portion, including impairment charges, from these seven minority investment entities that are not consolidated and are accounted for under the equity method were a loss of \$21,000 and a loss of \$1.4 million for the nine months ended September 30, 2018 and 2017, respectively.

Note 8. Stockholders' Equity

Condensed Consolidated Statement of Changes in Stockholders' Equity

(in thousands)

	Accumulated							
					Other	AXT, Inc.		Total
	Preferred	Comm	o A dditional Paid-In	Accumulated	d Compreher Income	ns iste ckholder	rs'Noncontrol	lli sg ockholders'
	Stock	Stock	Capital	Deficit	(Loss)	Equity	Interests	Equity
Balance as of			_					
December 31, 2017	\$ 3,532	\$ 39	\$ 231,679	\$ (54,837)	\$ 3,407	\$ 183,820	\$ 4,497	\$ 188,317
Common stock								
options exercised			264	_	_	264	_	264
Purchase of subsidiary shares from noncontrolling								
interest			187			187	(1,794)	(1,607)
Stock-based								
compensation			1,392	_	_	1,392	_	1,392
Net income	_			10,715		10,715	1,173	11,888
Other comprehensive loss Balance as of	_	_	_	_	(5,253)	(5,253)	(283)	(5,536)
September 30, 2018	\$ 3,532	\$ 39	\$ 233,522	\$ (44,122)	\$ (1,846)	\$ 191,125	\$ 3,593	\$ 194,718

There were no reclassification adjustments from accumulated other comprehensive income for the three and nine months ended September 30, 2018 and 2017.

Stock Repurchase Program

On October 27, 2014, our Board of Directors approved a stock repurchase program pursuant to which we may repurchase up to \$5.0 million of our outstanding common stock. These repurchases can be made from time to time in the open market and are funded from our existing cash balances and cash generated from operations. During 2015, we repurchased approximately 908,000 shares at an average price of \$2.52 per share for a total purchase price of approximately \$2.3 million under the stock repurchase program. No shares were repurchased during 2016 and 2017. During the three and nine months ended September 30, 2018, we did not repurchase any shares under the approved stock repurchase program. As of September 30, 2018, approximately \$2.7 million remained available for future repurchases under this program. Currently, we do not plan to repurchase additional shares.

Note 9. Stock-Based Compensation

We account for stock-based compensation in accordance with the provisions of ASC Topic 718, Compensation-Stock Compensation ("ASC 718"), which established accounting for stock-based awards exchanged for employee services. Stock-based compensation cost is measured at each grant date, based on the fair value of the award, and is recognized as expense over the employee's requisite service period of the award. All of our stock compensation is accounted for as an equity instrument.

Table of Contents

The following table summarizes compensation costs related to our stock-based awards (in thousands, except per share data):

	Three M	onths			
	Ended		Nine Months Ended		
	Septemb	er 30,	September	: 30,	
	2018	2017	2018	2017	
Cost of revenue	\$ 25	\$ 7	\$ 67	\$ 22	
Selling, general and administrative	361	280	1,098	788	
Research and development	75	52	227	151	
Total stock-based compensation	461	339	1,392	961	
Tax effect on stock-based compensation	_	_		_	
Net effect on net income	\$ 461	\$ 339	\$ 1,392	\$ 961	

As of September 30, 2018, the unamortized compensation costs related to unvested stock options granted to employees under our stock option plan was approximately \$1.2 million, net of estimated forfeitures of \$141,000. These costs will be amortized on a straight-line basis over a weighted-average period of approximately 1.8 years and will be adjusted for subsequent changes in estimated forfeitures. We did not capitalize any stock-based compensation to inventory as of September 30, 2018 and December 31, 2017 due to the immateriality of the amount.

We estimate the fair value of stock options using the Black-Scholes valuation model, consistent with the provisions of ASC 718. There were no options granted in the three and nine months ended September 30, 2018. There were no options granted in the three months ended September 30, 2017. There were 60,000 options with a weighted-average grant date fair values of \$2.76 per share granted in the nine months ended September 30, 2017. The fair values of our stock options granted to employees for nine months ended September 30, 2018 and 2017 were estimated using the following weighted-average assumptions:

	Nine Months Ended September 30,	l	Nine Months Ended September 30,	l
	2018		2017	
Expected term (in years)	_		5.9	
Volatility	_	%	46.71	%
Expected dividend	_	%	_	%
Risk-free interest rate		%	2.08	%

The following table summarizes the stock option transactions during the nine months ended September 30, 2018 (in thousands, except per share data):

Edgar Filing: AXT INC - Form 10-Q

Stock Options	Number of Options Outstanding	Weighted- average Exercise Price	Weighted average Remaining Contractual Life (in years)	Aggregate Intrinsic Value
Balance as of January 1, 2018	2,666	\$ 3.81	6.87	\$ 13,149
Granted	_	_		
Exercised	(93)	2.83		
Canceled and expired	(4)	5.21		
Balance as of September 30, 2018	2,569	\$ 3.84	6.19	\$ 8,847
Options vested as of September 30, 2018 and				
unvested options expected to vest, net of forfeitures	2,553	\$ 3.82	6.18	\$ 8,822
Options exercisable as of September 30, 2018	1,862	\$ 3.41	5.56	\$ 6,979

The aggregate intrinsic value in the table above represents the total pretax intrinsic value, based on our closing price of \$7.15 on September 30, 2018, which would have been received by the option holder had all option holders exercised their options on that date.

Restricted stock awards

A summary of activity related to restricted stock awards for the nine months ended September 30, 2018 is presented below (in thousands, except per share data):

		Weighted-Average	
		Grant Date	
Stock Awards	Shares	Fair	Value
Non-vested as of January 1, 2018	480	\$	7.13
Granted	35	\$	7.49
Vested	(49)	\$	6.19
Forfeited	(3)	\$	9.50
Non-vested as of September 30, 2018	463	\$	7.24

As of September 30, 2018, the unamortized compensation costs related to unvested restricted stock awards was approximately \$2.5 million, which is to be amortized on a straight-line basis over a weighted-average period of approximately 1.3 years.

Note 10. Net Income Per Share

Basic net income per share is computed using the weighted-average number of common shares outstanding during the periods less shares of common stock subject to repurchase and non-vested stock awards. Diluted net income per share is computed using the weighted-average number of common shares outstanding and potentially dilutive common shares outstanding during the periods. The dilutive effect of outstanding stock options and restricted stock awards is reflected in diluted earnings per share by application of the treasury stock method. Potentially dilutive common shares consist of common shares issuable upon the exercise of stock options and vesting of restricted stock awards. Potentially dilutive common shares are excluded from the computation of weighted-average number of common shares outstanding in net loss years, as their effect would be anti-dilutive to the computation.

A reconciliation of the numerators and denominators of the basic and diluted net income per share calculations is as follows (in thousands, except per share data):

Three Months Ended September 30,

Nine Months Ended September 30,

Edgar Filing: AXT INC - Form 10-Q

	2018	2017	2018	2017
Numerator:				
Net income attributable to AXT, Inc.	\$ 3,939	\$ 4,419	\$ 10,715	\$ 7,014
Less: Preferred stock dividends	(44)	(44)	(132)	(132)
Net income available to common stockholders	\$ 3,895	\$ 4,375	\$ 10,583	\$ 6,882
Denominator:				
Denominator for basic net income per share -				
weighted-average common shares	39,008	38,499	39,000	36,999
Effect of dilutive securities:				
Common stock options	1,207	1,416	1,196	1,283
Restricted stock awards	116	180	124	187
Denominator for dilutive net income per common shares	40,331	40,095	40,320	38,469
Net income attributable to AXT, Inc. per common share:				
Basic	\$ 0.10	\$ 0.11	\$ 0.27	\$ 0.19
Diluted	\$ 0.10	\$ 0.11	\$ 0.26	\$ 0.18
Options excluded from diluted net income per share as the				
impact is anti-dilutive	186	68	186	573
Restricted stock excluded from diluted net income per share				
as the impact is anti-dilutive	34	34	239	11
18				

Table of Contents

The 883,000 shares of \$0.001 par value Series A preferred stock issued and outstanding as of September 30, 2018 and December 31, 2017, valued at \$3,532,000, are non-voting and non-convertible preferred stock with a 5.0% cumulative annual dividend rate payable when declared by the board of directors and a \$4 per share liquidation preference over common stock, which must be paid before any distribution is made to common stockholders. These preferred shares were issued to Lyte Optronics, Inc. stockholders in connection with the completion of our acquisition of Lyte Optronics, Inc. on May 28, 1999.

Note 11. Segment Information and Foreign Operations

Segment Information

We operate in one segment for the design, development, manufacture and distribution of high-performance compound and single element semiconductor substrates and sale of raw materials integral to these substrates. In accordance with ASC Topic 280, Segment Reporting, our chief operating decision-maker has been identified as our Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the Company. Since we operate in one segment, all financial segment and product line information can be found in the condensed consolidated financial statements.

Product Information

The following table represents revenue amounts (in thousands) by product type:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2018	2017	2018	2017
Product Type:				
Substrates	\$ 22,802	\$ 22,377	\$ 63,769	\$ 58,095
Raw Materials and Others	5,824	5,791	16,396	14,246
Total	\$ 28,626	\$ 28,168	\$ 80,165	\$ 72,341

Geographical Information

The following table represents revenue amounts (in thousands) reported for products shipped to customers in the corresponding geographic region:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2018	2017	2018	2017
Geographical region:				
China	\$ 10,268	\$ 7,203	\$ 26,271	\$ 17,949
Taiwan	6,116	5,986	15,445	13,499
Europe (primarily Germany)	4,879	6,192	17,957	17,638
North America (primarily the United States)	2,967	2,159	7,052	5,909
Asia Pacific (excluding China, Taiwan and Japan)	2,334	2,934	6,399	7,650
Japan	2,062	3,694	7,041	9,696
Total	\$ 28,626	\$ 28,168	\$ 80,165	\$ 72,341

Table of Contents

Long-lived assets consist primarily of property, plant and equipment, and are attributed to the geographic location in which they are located. Long-lived assets, net of depreciation, by geographic region were as follows (in thousands):

	As of	20 Danamban 21
	2018	30,December 31, 2017
Long-lived assets by geographic region, net of depreciation:	2010	2017
North America	\$ 542	\$ 1,410
China	74,212	45,120
	\$ 74,754	\$ 46,530

Significant Customers

One customer, Landmark, represented 16% of our revenue for the three months ended September 30, 2018 while two customers, Landmark and Osram Opto, represented 16% and 10%, respectively, of our revenue for the three months ended September 30, 2017. Our top five customers, although not the same five customers for each period, represented 39% and 39% of our revenue for the three months ended September 30, 2018 and 2017, respectively.

One customer, Landmark, represented 13% of our revenue for the nine months ended September 30, 2018 while two customers, Landmark and Osram Opto, represented 12% and 11%, respectively, of our revenue for the nine months ended September 30, 2017. Our top five customers, although not the same five customers for each period, represented 36% and 37% of our revenue for the nine months ended September 30, 2018 and 2017, respectively.

We perform ongoing credit evaluations of our customers' financial condition, and limit the amount of credit extended when deemed necessary, but generally do not require collateral. Three customers accounted for 15%, 14% and 11% of our accounts receivable balance as of September 30, 2018, and one customer accounted for 12% of our accounts receivable balance as of December 31, 2017.

Note 12. Commitments and Contingencies

Indemnification Agreements

We have entered into indemnification agreements with our directors and officers that require us to indemnify our directors and officers against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of a culpable nature; to advance their expenses incurred as a result of any proceeding against them as to which they could be indemnified; and to obtain directors' and officers' insurance if available on reasonable terms, which we currently have in place.

Product Warranty

We provide warranties for our products for a specific period of time, generally twelve months, against material defects. We provide for the estimated future costs of warranty obligations in cost of sales when the related revenue is recognized. The accrued warranty costs represent the best estimate at the time of sale of the total costs that we expect to incur to repair or replace product parts that fail while still under warranty. The amount of accrued estimated warranty costs are primarily based on historical experience as to product failures as well as current information on repair costs. On a quarterly basis, we review the accrued balances and update the historical warranty cost trends. The following table reflects the change in our warranty accrual which is included in "Accrued liabilities" on the condensed consolidated balance sheets, during the three and nine months ended September 30, 2018 and 2017 (in thousands):

	Three M	onths			
	Ended		Nine Months Ended September 30,		
	Septemb	er 30,			
	2018	2017	2018	2017	
Beginning accrued product warranty	\$ 178	\$ 130	\$ 133	\$ 251	
Accruals for warranties issued	125	7	258	77	
Adjustments related to pre-existing warranties including expirations					
and changes in estimates	(10)	18	(33)	(114)	
Cost of warranty repair	(65)	(17)	(130)	(76)	
Ending accrued product warranty	\$ 228	\$ 138	\$ 228	\$ 138	

Contractual Obligations

We lease certain office space, warehouse facilities and equipment under long-term operating leases expiring at various dates through April 2023. The majority of our lease obligations relate to our lease agreement for the facility in Fremont, California with approximately 19,467 square feet. The term of the original lease for this facility would have expired in 2017. According to the lease agreement, we had an option to extend the term of the lease for an additional three years. In May 2017, we exercised this option and the lease was extended for an additional three year term. All terms of this lease otherwise remain the same and the term of this lease will expire in 2020. Under the terms of the lease agreement, in 2020, we will have the option to extend the term of the lease for an additional three years.

We entered into a royalty agreement with a competitor effective December 3, 2010 with a term of eight years, terminating December 31, 2018. We and our related companies are granted a worldwide, nonexclusive, royalty bearing, irrevocable license to certain patents for the term of the agreement. We shall pay up to \$7.0 million of royalty payments over eight years that began in 2011 based on future royalty bearing sales. This royalty agreement contains a clause that allows us to claim a credit, starting in 2013, in the event that the royalty bearing sales for the year are lower than a pre-determined amount set forth in this agreement.

The following table summarizes our contractual obligations as of September 30, 2018 (in thousands):

	Payments due by period								
				1-3	4-5	Mo	re than		
Contractual Obligations	Total	Les	s than 1 year	years	years	5 years			
Operating leases	\$ 452	\$	193	\$ 233	\$ 26	\$	_		
Royalty agreement	144		144	_					
Total	\$ 596	\$	337	\$ 233	\$ 26	\$			

Land Purchase and Investment Agreement

We are in the process of relocating our gallium arsenide production line to Dingxing, China. In addition to a land rights and building purchase agreement that we entered into with a private real estate development company to acquire our new manufacturing facility, we also entered into a cooperation agreement with the Dingxing local government. In addition to pledging its full support and cooperation, the Dingxing local government will issue certain credits or rebates to us as we achieve certain milestones. We, in turn, agreed to hire local workers over time, pay taxes when due and eventually demonstrate a total investment of approximately \$90 million in value, assets and capital. The investment will include cash

Table of Contents

paid for the land and buildings, cash on deposit in our name at local banks, the gross value of new and used equipment (including future equipment that might be used for indium phosphide and germanium substrates production), the deemed value for our customer list or the end user of our substrates (for example, the end users of 3-D sensing VCSELs (vertical cavity surface emitting lasers)), a deemed value for employment of local citizens, a deemed value for our proprietary process technology, other intellectual property, other intangibles and additional items of value. There is no timeline or deadline by which this must be accomplished, rather it is a good faith covenant entered into between AXT and the Dingxing local government. Further, there is no specific penalty contemplated if either party breaches the agreement. However, the agreement does state that each party has a right to seek from the other party compensation for losses. Under certain conditions, the Dingxing local government may purchase the land and building at the appraised value. We believe that such cooperation agreements are normal, customary and usual in China and that the future valuation is flexible. We have a similar agreement with the city of Kazuo, China, although on a smaller scale. The total investment targeted by AXT in Kazuo is approximately \$15 million in value, assets and capital. In addition, BoYu has a similar agreement with the city of Kazuo. The total investment targeted by BoYu in Kazuo is approximately \$8 million in value, assets and capital.

Purchase Obligations with Penalties for Cancellation

In the normal course of business, we issue purchase orders to various suppliers. In certain cases, we may incur a penalty if we cancel the purchase order. As of September 30, 2018, we do not have any outstanding purchase orders that will incur a penalty if cancelled by the Company.

Bank Loans

In September 2018, Tongmei entered into a credit facility with Industrial and Commercial Bank of China ("ICBC") in China with a \$2.9 million line of credit at an annual interest rate of approximately 0.04% over the current Loan Prime Rate published by ICBC. Accrued interest is calculated and paid monthly. The annual interest rate was approximately 4.4% as of September 30, 2018. This credit line is secured by Tongmei's land-use right and all of its buildings located at its facility in Beijing. The primary intended use of the credit facility is for general purposes, which may include working capital, capital expenditures and other corporate expenses.

On September 30, 2018, we borrowed \$291,000 against this credit line. The repayment of the full amount is due in September 2019. As of September 30, 2018, \$291,000 was included in "Bank loan" in our condensed consolidated balance sheets.

Legal Proceedings

From time to time we may be involved in judicial or administrative proceedings concerning matters arising in the ordinary course of business. We do not expect that any of these matters, individually or in the aggregate, will have a material adverse effect on our business, financial condition, cash flows or results of operations.

Note 13. Foreign Exchange Transaction Gains/Losses

We incurred a foreign currency transaction exchange gain of \$116,000 and exchange loss of \$339,000 for the three months ended September 30, 2018 and 2017, respectively. We incurred a foreign currency transaction exchange loss of \$224,000 and a loss of \$414,000 for the nine months ended September 30, 2018 and 2017, respectively. These amounts are included in "Other (expense) income, net" on our condensed consolidated statements of operations.

Note 14. Income Taxes

We account for income taxes in accordance with ASC Topic 740, Income Taxes ("ASC 740"), which requires that deferred tax assets and liabilities be recognized using enacted tax rates for the effect of temporary differences between the book and tax bases of recorded assets and liabilities. ASC 740 also requires that deferred tax assets be reduced by a valuation allowance if it is more likely than not that a portion of the deferred tax asset will not be realized. Our deferred tax assets have been reduced to zero by a valuation allowance.

Table of Contents

The Tax Act enacted in December 2017 introduced significant changes to U.S. income tax law. Effective 2018, the Tax Act reduced the U.S. statutory tax rate from 35% to 21% and created new taxes on certain foreign-sourced earnings and certain intercompany payments.

We provide for income taxes based upon the geographic composition of worldwide earnings and tax regulations governing each region, particularly China. The calculation of tax liabilities involves significant judgment in estimating the impact of uncertainties in the application of complex tax laws, particularly in foreign countries such as China.

We recognize interest and penalties related to uncertain tax positions in income tax expense. Income tax expense for the three and nine months ended September 30, 2018 includes no interest and penalties. As of September 30, 2018, we have no accrued interest and penalties related to uncertain tax positions. We file income tax returns in the U.S. federal, various states and foreign jurisdictions. We have substantially concluded all U.S. federal and state income tax matters through 2002 and 2013, respectively.

Provision for income taxes for the three and nine months ended September 30, 2018 was mostly related to our wholly owned China subsidiaries and our three partially owned subsidiaries in China. Besides the state tax liabilities, no income taxes or benefits have been provided for U.S. operations for the three and nine months ended September 30, 2018 due to the loss in the U.S. and the uncertainty of generating future profit in the U.S., which has resulted in our deferred tax asset being fully reserved.

On December 22, 2017, the Tax Cuts & Jobs Act ("TCJA") was enacted into law, which significantly changes existing U.S. tax law and includes numerous provisions that affect our business, such as imposing a one-time transition tax on deemed repatriation of deferred foreign income, reducing the U.S. federal statutory tax rate, and adopting a territorial tax system. The TCJA includes a provision to tax global intangible low-taxed income ("GILTI") of foreign subsidiaries and a base erosion anti-abuse tax ("BEAT") measure that taxes certain payments between a U.S. corporation and its subsidiaries. The GILTI and BEAT provisions of the TCJA is effective for us beginning January 1, 2018. We have included an estimate of the current GILTI impact in our September 30, 2018 tax provision. We are not subject to BEAT provision.

Note 15. Revenue

Revenue Recognition

We manufacture and sell high-performance compound semiconductor substrates including indium phosphide, gallium arsenide and germanium wafers, and our three consolidated subsidiaries sell certain raw materials, including 99.99% pure gallium (4N Ga), high purity gallium (7N Ga), pyrolytic boron nitride (pBN) crucibles and boron oxide (B2O3). After we ship our products, there are no remaining obligations or customer acceptance requirements that would

preclude revenue recognition. Our products are typically sold pursuant to purchase orders placed by our customers, and our terms and conditions of sale do not require customer acceptance. We account for a contract with a customer when there is a legally enforceable contract, which could be the customer's purchase order, the rights of the parties are identified, the contract has commercial terms, and collectibility of the contract consideration is probable. The majority of our contracts have a single performance obligation to transfer products and are short term in nature, usually less than one year. Our revenue is measured based on the consideration specified in the contract with each customer in exchange for transferring products that is generally based upon a negotiated, formula, list or fixed price. Revenue is recognized when control of the promised goods is transferred to our customer, which is either upon shipment from our dock, receipt at the customer's dock, or removal from consignment inventory at the customer's location, in an amount that reflects the consideration we expect to be entitled to receive in exchange for those goods.

We have elected to account for shipping and handling as activities to fulfill the promise to transfer the goods. As such, shipping and handling fees billed to customers in a sales transaction are recorded in revenue and shipping and handling costs incurred are recorded in cost of revenue. Sales taxes and value added taxes in foreign jurisdictions that are collected from customers and remitted to governmental authorities are accounted for on a net basis and, therefore, are excluded from net sales.

Table of Contents

We do not provide training, installation or commissioning services. We provide for future returns based on historical data, prior experience, current economic trends and changes in customer demand at the time revenue is recognized. We do not recognize any asset associated with the incremental cost of obtaining revenue generating customer contracts. As such, sales commissions are expensed as incurred, given that the expected period of benefit is less than one year.

On January 1, 2018, we adopted ASC Topic 606, Revenue from Contracts with Customers ("ASC 606"), and its related amendments, using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018. The adoption of ASC 606, using the modified retrospective approach, had no significant impact to our accumulated deficit as of January 1, 2018 and no significant impact to the total net cash from or used in operating, investing, or financing activities within the condensed consolidated statements of cash flows. In connection with this adoption on January 1, 2018, we reclassified our refund liabilities relating to sales with a right of return in the amount of \$169,000 to present it separately from "Accounts receivables" and included it in "Accrued liabilities" on the condensed consolidated balance sheets.

Contract Balances

We receive payments from customers based on a billing schedule as established in our contracts. Contract assets are recorded when we have a conditional right to consideration for our completed performance under the contracts. Accounts receivables are recorded when the right to this consideration becomes unconditional. We do not have any material contract assets as of September 30, 2018.

Contract liabilities Revenue recognized in the nine and three months period ended as of September 30, 2018 from:	September 30, 2018 \$ (648)	2018	December 31, 2017 \$ (924)
Amounts included in contract liabilities at the beginning of the period	\$ 776	\$ ₄₂₅	Not Applicable

Disaggregated Revenue

In general, revenue disaggregated by product types and geography (See Note 11) is aligned according to the nature and economic characteristics of our business and provides meaningful disaggregation of our results of operations. Since we operate in one segment, all financial segment and product line information can be found in the condensed consolidated financial statements.

Practical Expedients and Exemptions

As part of our adoption of ASC 606, we elected to use the following practical expedients: (i) not to adjust the promised amount of consideration for the effects of a significant financing component when we expect, at contract inception, that the period between our transfer of a promised product or service to a customer and when the customer pays for that product or service will be one year or less; (ii) to expense costs as incurred for costs to obtain a contract when the amortization period would have been one year or less; (iii) not to assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer.

In addition, we do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less.

Table of Contents

Note 16. Bank Loans

In September 2018, Tongmei entered into a credit facility with ICBC in China with a \$2.9 million line of credit at an annual interest rate of approximately 0.04% over the current Loan Prime Rate by published by ICBC. Accrued interest is calculated and paid monthly. The annual interest rate was approximately 4.4% as of September 30, 2018. This credit line is secured by Tongmei's land-use right and all of its buildings located at its facility in Beijing. The primary intended use of the credit facility is for general purposes, which may include working capital, capital expenditures and other corporate expenses.

On September 30, 2018, we borrowed \$291,000 against this credit line. The repayment of the full amount is due in September 2019. As of September 30, 2018, \$291,000 was included in "Bank loan" in our condensed consolidated balance sheets.

Note 17. Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board ("FASB") issued new guidance related to revenue recognition, which outlines a comprehensive revenue recognition model and supersedes most current revenue recognition guidance. The new guidance requires a company to recognize revenue as control of goods or services transfers to a customer at an amount that reflects the expected consideration to be received in exchange for those goods or services. In August 2015, the FASB issued an amendment to defer the effective date of the guidance. The guidance became effective in the first quarter of our fiscal year 2018. The new standard creates a single source of revenue guidance under accounting principles generally accepted in the United States, eliminating industry-specific guidance.

The underlying principle of the standard is to recognize revenue when a customer obtains control of promised goods or services at an amount that reflects the consideration that is expected to be received in exchange for those goods or services. An entity should apply a five-step approach for recognizing revenue as follows (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, the entity satisfies a performance obligation. The standard also requires increased disclosures including the nature, amount, timing, and uncertainty of revenues and cash flows related to contracts with customers. The standard allows two methods of adoption: (1) retrospectively to each prior period presented ("full retrospective method"), or (2) retrospectively with the cumulative effect recognized in retained earnings as of the date of adoption ("modified retrospective method").

With regard to Accounting Standards Update ("ASU") 2014-09 Revenue from Contracts with Customers, we established a crossfunctional team to assess the potential impact of the new standard and reviewed current accounting policies and practices to identify potential differences that would result from applying the requirements of the new standard to revenue contracts and identifying appropriate changes to the business processes, systems and controls to support revenue recognition and disclosure requirements under the new standard. We completed our evaluation of the potential impact on business processes, systems, controls and condensed consolidated financial statements of the new revenue standard and have concluded there are no significant changes to our condensed consolidated statement of

operations. In connection with this adoption on January 1, 2018, we reclassified our refund liabilities relating to sales with a right of return in the amount of \$169,000 to present it separately from "Accounts receivables" and included it in "Accrued liabilities" on the condensed consolidated balance sheets. We adopted this standard on January 1, 2018 using the modified retrospective method (See Note 15).

In January 2016, the FASB issued ASU 2016-01, which made changes to the accounting for financial instruments that primarily affect equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. The amendments in this update supersede the guidance to classify equity securities with readily determinable fair values into different categories (that is, trading or available-for-sale) and require equity securities to be measured at fair value with changes in the fair value recognized through net income. The standard amends financial reporting by providing relevant information about an entity's equity investments and reducing the number of items that are recognized in other comprehensive income. This update became effective for annual periods beginning after December 15, 2017, and interim periods within those annual periods. We adopted this guidance effective January 1, 2018 and it did not have a significant impact on our condensed consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, which replaces the existing guidance for leases. The new standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years and requires retrospective application. We will adopt this standard in fiscal 2019 and are currently evaluating the impact of the guidance on our condensed consolidated financial statements.

In August 2016, the FASB issued ASU No. 2016-15, which reduces diversity in practice where the FASB was either unclear or did not provide specific guidance for classifying cash payments and receipts in the statement of cash flows for eight specific transactions. The guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years and requires retrospective application with early application permitted. We adopted this guidance effective January 1, 2018 and it did not have a significant impact on our condensed consolidated financial statements.

In October 2016, the FASB issued ASU No. 2016-16, which clarifies the accounting for the current and deferred income taxes for an intra-entity transfer of an asset other than inventory. The guidance is effective for fiscal years beginning after December 15, 2017, including periods within those fiscal years and requires retrospective application with early application permitted. We adopted this guidance effective January 1, 2018 and it did not have a significant impact on our condensed consolidated financial statements.

In January 2017, the FASB issued ASU No. 2017-01, which clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill, and consolidation. The guidance is effective for fiscal years beginning after December 15, 2017, including periods within those fiscal years and requires retrospective application with early application permitted. We adopted this guidance effective January 1, 2018 and it did not have a significant impact on our condensed consolidated financial statements.

In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. The guidance provides clarity and reduces diversity in practice and cost and complexity when accounting for a change to the terms or conditions of a share-based payment award. The guidance is effective for fiscal years beginning after December 15, 2017. We adopted this guidance effective January 1, 2018 and it did not have a significant impact on our condensed consolidated financial statements.

Note 18. Subsequent Events

On November 6, 2018, the Company entered into a Credit Agreement, by and between the Company and Wells Fargo Bank, National Association, which established a \$10 million revolving line of credit. The line of credit is collateralized by substantially all of the assets of the Company located within the United States, subject to certain exceptions. The line of credit has a two year term and any advances thereunder will bear interest at a rate based on the daily one month London Inter-bank Offered Rate ("LIBOR") plus two percent (2.0%). As of November 7, 2018, no proceeds have been drawn down on this line of credit.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This quarterly report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements relating to our expectations regarding results of operations, customer demand, customer qualifications of our products, our ability to expand our markets or increase sales, the development of new products, applications, enhancements or technologies, the life cycles of our products and applications, gross margins, expense levels, the impact of the adoption of certain accounting pronouncements, our investments in capital projects, our ability to relocate our gallium arsenide production line in a timely and orderly manner, our estimated construction and relocation costs with respect to the relocation of our gallium arsenide production line, our ability to have customers re-qualify substrates from our new manufacturing location in Dingxing, China, trade wars, tariffs, the political-economical environment, and our belief that we have adequate cash and investments to meet our needs over the next 12 months are forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "goals," "should," "co "would," "could" and similar expressions or variations of such words are intended to identify forward looking statements, but are not the exclusive means of identifying forward looking statements in this quarterly report. Additionally, statements concerning future matters such as our strategy, plans, industry trends and the impact of trends and economic cycles on our business are forward-looking statements. All forward-looking statements are based upon management's views as of the date of this quarterly report and are subject to risks and uncertainties that could cause actual results to differ materially from historical results or those anticipated in such forward-looking statements. Such risks and uncertainties include those set forth under the section entitled "Risk Factors" in Item 1A below, as well as those discussed elsewhere in this quarterly report, and identify important factors that could disrupt or injure our business or cause actual results to differ materially from those predicted in any such forward-looking statements.

These forward-looking statements are not guarantees of future performance. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Readers are urged to carefully review and consider the various disclosures made in this report, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects. We undertake no obligation to revise or update any forward looking statements in order to reflect any development, event or circumstance that may arise after the date of this report. This discussion should be read in conjunction with Management's Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2017 and the condensed consolidated financial statements included elsewhere in this report.

Table of Contents

Overview

AXT, Inc. ("AXT", "the company", "we," "us," and "our" refer to AXT, Inc. and its consolidated subsidiaries) is a worldwide materials science company that develops and produces high-performance compound and single element semiconductor substrates, also known as wafers. Our consolidated subsidiaries produce and sell certain raw materials some of which are used in our substrate manufacturing process and some of which are sold to other companies.

Our substrate wafers are used when a typical silicon substrate wafer cannot meet the performance requirements of a semiconductor or optoelectronic device. The dominant substrates used in producing semiconductor chips and other electronic circuits are made from silicon. However, certain chips may become too hot or perform their function too slowly if silicon is used as the base material. In addition, optoelectronic applications, such as LED lighting and chip-based lasers, do not use silicon substrates because they require a wave form frequency that cannot be achieved using silicon. Alternative or specialty materials are used to replace silicon as the preferred base in these situations. Our wafers provide such alternative or specialty materials. We do not design or manufacture the chips. We add value by researching, developing and producing the specialty material wafers. We have two product lines: specialty material substrates and raw materials integral to these substrates. Our compound substrates combine indium with phosphorous (indium phosphide: InP) or gallium with arsenic (gallium arsenide: GaAs). Our single element substrates are made from germanium (Ge).

Semi-insulating GaAs is used to create various high speed microwave components, including power amplifier chips used in cell phones, satellite communications and broadcast television applications. Semi-conducting GaAs substrates are used to create opto-electronic products, including high brightness light emitting diodes (HBLEDs) that are often used to backlight wireless handsets and liquid crystal display (LCD) TVs and also used for automotive panels, signage, display and lighting applications. A possible new application for semi-conducting GaAs is 3-D sensing chips using VCSELs (vertical cavity surface emitting lasers) as an array of lasers on a single chip that could be used in cell phones and other devices. InP is a high performance semiconductor substrate used in broadband and fiber optic applications and data center connectivity. In recent years, InP demand has increased. Ge substrates are used in applications such as solar cells for space and terrestrial photovoltaic applications.

Our raw materials include both raw gallium and purified gallium. We use purified gallium in producing our GaAs substrates and sell both raw gallium and purified gallium in the open market to other companies for use in magnetic materials, high temperature thermometers, single crystal ingots including gallium arsenide, gallium nitride, gallium antimonide, gallium phosphide, and other materials and alloys. We also produce pyrolytic boron nitride (pBN) crucibles used in the high temperature (typically in the range 500 C to 1,500 C) growth process of single crystal ingots and epitaxial layer growth in MBE (Molecular Beam Epitaxy) reactors. We use these pBN crucibles in our own ingot growth processes and also sell them in the open market to other companies. Our substrate product group generated 80%, 81% and 75% of our revenue and our raw materials product group generated 20%, 19% and 25% for 2017, 2016 and 2015, respectively.

Table of Contents

The following chart shows our substrate products and their materials, diameters and illustrative applications and shows our raw materials group primary products and their illustrative uses and applications.

Products		
Substrate Group	Wafer Diameter	Sample of Applications
Indium Phosphide (InP)	2", 3", 4"	 Fiber optic lasers and detectors Passive Optical Networks (PONs) Data center connectivity using light/lasers Silicon photonics Photonic Integrated circuits (PICs) High efficiency terrestrial solar cells (CPV) RF amplifier and switching (military wireless and potential 5G) Infrared light-emitting diode (LEDs) motion control Infrared thermal imaging
Gallium Arsenide (GaAs - semi-insulating)	1", 2", 3", 4",	 5 Power amplifiers for wireless devices Direct broadcast television High-performance transistors Satellite communications High efficiency solar cells for drones and automobiles
Gallium Arsenide (GaAs - semi-conducting)	1", 2", 3", 4", 6"	-
Germanium (Ge)	2", 4", 6"	 Satellite solar cells Optical sensors and detectors Terrestrial concentrated photo voltaic (CPV) cells Multi-junction solar cells for satellites Infrared detectors
Raw Materials Group		
4N raw gallium		 Magnetic materials High temperature thermometers Low melting point alloys Optical glass Infrared detectors
6N+ purified gallium Boron trioxide (B2O3)		 Key material in single crystal ingots such as: Gallium Arsenide (GaAs) Gallium Nitride (GaN) Gallium Antimonide (GaSb) Gallium Phosphide (GaP)
Doron modiue (D2O3)		

	semiconductors
Gallium-Magnesium alloy	• Used for the synthesis of organo-gallium compounds in epitaxial
	growth on semiconductor wafers
pyrolytic boron nitride (pBN)	 Used when growing single-crystal compound semiconductor
crucibles	ingots

- ngle-crystal compound semiconductor ingots
- Used when growing epitaxial layers in MBE reactors

• Encapsulant in the ingot growth of III-V compound

• Metal-Organic Chemical Vapour Deposition (MOCVD) reactors and organic light-emitting diode (OLED) rings

29

pBN insulating parts

We manufacture all of our products in the People's Republic of China (PRC or China), which generally has favorable costs for facilities and labor compared with comparable facilities in the United States, Europe or Japan. Our supply chain includes partial ownership of 10 companies in China (subsidiaries/joint ventures). We believe this supply chain arrangement provides us with pricing advantages, reliable supply, market trend visibility and better sourcing lead-times for key raw materials central to manufacturing our substrates. Our subsidiaries and joint venture companies produce materials, including raw gallium (4N Ga), high purity gallium (6N Ga), arsenic, germanium, germanium dioxide, pyrolytic boron nitride (pBN) crucibles and boron oxide (B2O3). Our ownership and the ownership held by our consolidated subsidiaries in these companies range from 97% to 20%. We have board representation in all 10 of these companies. We consolidate the companies in which we have either a controlling financial interest, or majority financial interest combined with the ability to exercise substantive control over the operation or financial decisions made by such companies. We use the equity method to account for companies in which we have smaller financial interest and have the ability to exercise significant influence, but not control, over such companies. We purchase portions of the materials produced by these companies for our own use and they sell the remainder of their production to third parties.

The Beijing city government is expanding its offices into the area where our manufacturing facility is currently located and is in the process of moving thousands of government employees into this area. The Beijing city government desires to upgrade this area and has applied pressure on manufacturing companies to relocate, including us. We are cooperating with the government and, in accordance with our relocation plan, are relocating our gallium arsenide production line. On September 12, 2017, we announced that we completed the purchase of a new manufacturing site in the city of Dingxing, China. Dingxing, located in the province of Hebei and under the jurisdiction of the prefecture-level city of Baoding, is approximately a 90 minute drive south of our current Beijing location. The Dingxing site is approximately 18.75 acres and included three existing buildings, which comprise approximately 140,000 sq. feet of production space and 50,000 sq. feet designated for offices and dormitories. We are constructing a fourth building at this site. We have also acquired property in the city of Kazuo, China, located in the province of Liaoning near the Inner Mongolia Autonomous Region and under the jurisdiction of the prefecture-level city of Chaoyang. Initially, the Kazuo site will be used to perform the first step in producing gallium arsenide, which is the blending or synthesis of gallium and arsenic ("poly synthesis"). We also intend to use the Kazuo site for ingot growth. The Dingxing site will focus on wafer processing and the ingots will be shipped from our Kazuo site to our Dingxing site. Although our current focus is on relocating our gallium arsenide production line, we are also relocating our germanium production line and will consider moving our indium phosphide production line in the future. Additional environmental permits, regulatory approvals and zoning conformance applications are in process.

To mitigate our risks and maintain our production schedule, we are moving our gallium arsenide equipment in stages so that we will continue to produce our gallium arsenide products at our Beijing site and then subsequently transfer increasing volume to the new sites. This approach will also minimize any disruption to our customers. We intend to complete this relocation in the first half of 2019. The relocation of our gallium arsenide production line requires us to accurately execute our relocation plan. Our major customers will want to examine and qualify the wafer substrates produced from the new manufacturing line before placing volume purchase orders for such products. We have made available to certain customers initial gallium arsenide qualification wafers produced from the new manufacturing line. A failure to properly execute our relocation plan could result in disruption to our production and have a material adverse impact on our revenue and our results of operations and financial condition. If we fail to meet the product qualification requirements of a customer, we may lose sales to that customer. Our reputation may also be damaged. Any loss of sales could have a material adverse effect on our revenue and our results of operations and financial condition.

On September 24, 2018, the Trump Administration announced a list of thousands of categories of goods that will face tariffs of 10%. All of our wafer substrates are manufactured in China and for the three months ended September 30, 2018, approximately 10% of our revenue was generated by sales to customers in North America, primarily in the U.S. Our inbound products to the U.S. are now subject to a 10% tariff assessed on the customs value of the goods as imported by us, effective approximately September 24, 2018. Although we do not believe the initial impact of approximately \$150,000 per quarter is material, the future impact of tariffs and trade wars is uncertain. The tariffs are expected to increase to 25% in January 2019. We may be required to raise prices, which may result in the loss of customers and our business, financial condition and results of operations may be materially harmed. Additionally, the Trump Administration continues to signal that it may alter trade agreements and terms between China and the United States, including limiting trade with China, and may impose additional tariffs on imports from China.

Table of Contents

Critical Accounting Policies and Estimates

We prepare our condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. Accordingly, we make estimates, assumptions and judgments that affect the amounts reported on our condensed consolidated financial statements. These estimates, assumptions and judgments about future events and their effects on our results cannot be determined with certainty, and are made based upon our historical experience and on other assumptions that are believed to be reasonable under the circumstances. These estimates may change as new events occur or additional information is obtained, and we may periodically be faced with uncertainties, the outcomes of which are not within our control and may not be known for a prolonged period of time.

We have identified the policies below as critical to our business operations and understanding of our financial condition and results of operations. Critical accounting policies are material to the presentation of our condensed consolidated financial statements and require us to make difficult, subjective or complex judgments that could have a material effect on our financial reports and results of operations. They may require us to make assumptions about matters that are highly uncertain at the time of the estimate. Different estimates that we could have used, or changes in the estimate that are reasonably likely to occur, may have a material impact on our financial condition or results of operations.

Revenue Recognition

We manufacture and sell high-performance compound semiconductor substrates, including indium phosphide, gallium arsenide and germanium wafers, and our three consolidated subsidiaries sell certain raw materials, including 99.99% pure gallium (4N Ga), high purity gallium (7N Ga), pyrolytic boron nitride (pBN) crucibles and boron oxide (B2O3). After we ship our products, there are no remaining obligations or customer acceptance requirements that would preclude revenue recognition. Our products are typically sold pursuant to purchase orders placed by our customers, and our terms and conditions of sale do not require customer acceptance. We account for a contract with a customer when there is a legally enforceable contract, which could be the customer's purchase order, the rights of the parties are identified, the contract has commercial terms, and collectibility of the contract consideration is probable. The majority of our contracts have a single performance obligation to transfer products and are short term in nature, usually less than one year.

Our revenue is measured based on the consideration specified in the contract with each customer in exchange for transferring products that is generally based upon a negotiated, formula, list or fixed price. Revenue is recognized when control of the promised goods is transferred to our customer, which is either upon shipment from our dock, receipt at the customer's dock, or removal from consignment inventory at the customer's location, in an amount that reflects the consideration we expect to be entitled to receive in exchange for those goods.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable are recorded at the invoiced amount and are not interest bearing. We periodically review the likelihood of collection on our accounts receivable balances and provide an allowance for doubtful accounts receivable primarily based upon the age of these accounts. We evaluate receivables from U.S. customers with an emphasis on balances in excess of 90 days and for receivables from customers located outside the U.S. with an emphasis on balances in excess of 120 days and establish a reserve allowance on the receivable balances if needed. The reason for the difference in the evaluation of receivables between foreign and U.S. customers is that U.S. customers have historically made payments in a shorter period of time than foreign customers. Foreign business practices generally require us to allow customer payment terms that are longer than those accepted in the United States. We assess the probability of collection based on a number of factors, including the length of time a receivable balance has been outstanding, our past history with the customer and their credit-worthiness.

We exercise judgment when determining the adequacy of our reserves as we evaluate historical bad debt trends, general economic conditions in the United States and internationally, and changes in customer financial conditions. Uncollectible receivables are recorded as bad debt expense when all efforts to collect have been exhausted and recoveries are recognized when they are received. As of September 30, 2018 and December 31, 2017, our accounts

Table of Contents

receivable, net balance was \$23.3 million and \$22.8 million, respectively, which was net of an allowance for doubtful accounts of \$358,000 and \$358,000, respectively. If actual uncollectible accounts differ substantially from our estimates, revisions to the estimated allowance for doubtful accounts would be required, which could have a material impact on our financial results for the future periods.

Historically, our allowance for sales returns reserve was deducted from gross accounts receivable. Upon adoption, on January 1, 2018, of the new revenue recognition guidance we reclassified our sales returns reserve to accrued liabilities. As of September 30, 2018 and December 31, 2017, the balance was \$37,000 and \$169,000, respectively.

Product Warranty

We maintain a product warranty based upon our claims experience during the prior twelve months and any pending claims and returns of which we are aware. Warranty costs are accrued at the time revenue is recognized. As of September 30, 2018 and December 31, 2017, accrued product warranties totaled \$228,000 and \$133,000, respectively.

The increase in accrued product warranties is primarily attributable to increased claims for quality issues experienced by customers. If actual warranty costs or pending new claims differ substantially from our estimates, revisions to the estimated warranty liability would be required, which could have a material impact on our financial condition and results of operations for future periods.

Inventory Valuation

Inventories are stated at the lower of cost (approximated by standard cost) or net realizable value. Cost is determined using the weighted-average cost method. Our inventory consists of raw materials as well as finished goods and work in process that include material, labor and manufacturing overhead costs. We routinely evaluate the levels of our inventory in light of current market conditions in order to identify excess and obsolete inventory, and we provide a valuation allowance for certain inventories based upon the age and quality of the product and the projections for sale of the completed products. As of September 30, 2018 and December 31, 2017, we had an inventory reserve of \$14.4 million and \$13.3 million, respectively, for excess and obsolete inventory and \$40,000 and \$291,000, respectively, for lower of cost or net realizable value reserves. If actual demand for our products were to be substantially lower than estimated, additional inventory adjustments for excess or obsolete inventory might be required, which could have a material impact on our business, financial condition and results of operations.

Impairment of Investments

We classify marketable investments in debt and equity securities as available-for-sale securities in accordance with Accounting Standards Codification ("ASC") Topic 320, Investments - Debt and Equity Securities ("ASC 320"). All available-for-sale securities with a quoted market value below cost (or adjusted cost) are reviewed in order to determine whether the decline is other-than-temporary. Factors considered in determining whether a loss is temporary include the magnitude of the decline in market value, the length of time the market value has been below cost (or adjusted cost), credit quality, and our ability and intent to hold the securities for a period of time sufficient to allow for any anticipated recovery in market value.

We also invest in equity instruments of privately-held companies in China for business and strategic purposes. Investments in our unconsolidated joint venture companies are classified as other assets and accounted for under either the equity or cost method, depending on whether we have the ability to exercise significant influence over their operations or financial decisions. We monitor our investments for impairment and record reductions in carrying value when events or changes in circumstances indicate that the carrying value may not be recoverable. Determination of impairment is highly subjective and is based on a number of factors, including an assessment of the strength of each company's management, the length of time and extent to which the fair value has been less than our cost basis, the financial condition and near-term prospects of the company, fundamental changes to the business prospects of the company, share prices of subsequent offerings, and our intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in our carrying value.

Table of Contents

There were no impairment charges in the three and nine months ended September 30, 2018. The nine months ended September 30, 2017 include an impairment charge of \$313,000 for one of the joint ventures that produces gallium. During the first quarter of 2017, management determined it unlikely that this company will recover from the difficult pricing environment and we had written the investment down to zero.

Fair Value of Investments

ASC 820, Fair Value Measurements and Disclosures ("ASC 820") establishes three levels of inputs that may be used to measure fair value.

Level 1 instruments represent quoted prices in active markets. Therefore, determining fair value for Level 1 instruments does not require significant management judgment, and the estimation is not difficult.

Level 2 instruments include observable inputs other than Level 1 prices, such as quoted prices for identical instruments in markets with insufficient volume or infrequent transactions (less active markets), issuer bank statements, credit ratings, non-binding market consensus prices that can be corroborated with observable market data, model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated with observable market data for substantially the full term of the assets or liabilities, or quoted prices for similar assets or liabilities. These Level 2 instruments require more management judgment and subjectivity compared to Level 1 instruments, including:

- Determining which instruments are most similar to the instrument being priced requires management to identify a
 sample of similar securities based on the coupon rates, maturity, issuer, credit rating, and instrument type, and
 subjectively select an individual security or multiple securities that are deemed most similar to the security being
 priced.
- Determining which model-derived valuations to use in determining fair value requires management judgment. When
 observable market prices for identical securities or similar securities are not available, we price our marketable debt
 instruments using non-binding market consensus prices that are corroborated with observable market data or pricing
 models, such as discounted cash flow models, with all significant inputs derived from or corroborated with
 observable market data.

Level 3 instruments include unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities. The determination of fair value for Level 3 instruments requires the most management judgment and subjectivity.

We place short-term foreign currency hedges that are intended to offset the potential cash exposure related to fluctuations in the exchange rate between the United States dollar and Japanese yen. We measure the fair value of these foreign currency hedges at each month end and quarter end using current exchange rates and in accordance with generally accepted accounting principles. At quarter end any foreign currency hedges not settled are netted in "Accrued liabilities" on the condensed consolidated balance sheet and classified as Level 3 assets and liabilities. As of September 30, 2018 the net change in fair value from the placement of the hedge to settlement at each month end during the quarter had a de minimis impact to the consolidated results.

There have been no transfers between fair value measurement levels during the three and nine months ended September 30, 2018 and 2017.

Impairment of Long-Lived Assets

We evaluate the recoverability of property, equipment and intangible assets in accordance with ASC Topic 360, Property, Plant and Equipment ("ASC 360"). When events and circumstances indicate that long-lived assets may be impaired, we compare the carrying value of the long-lived assets to the projection of future undiscounted cash flows attributable to these assets. In the event that the carrying value exceeds the future undiscounted cash flows, we record an impairment charge against income equal to the excess of the carrying value over the assets' fair value. Fair

Table of Contents

values are determined based on quoted market values, discounted cash flows or internal and external appraisals, as applicable. Assets held for sale are carried at the lower of carrying value or estimated net realizable value. We had no assets held for sale on the condensed consolidated balance sheets as of September 30, 2018 and December 31, 2017.

Stock-based Compensation

We account for stock-based compensation in accordance with ASC Topic 718, Stock-based Compensation ("ASC 718"). Share-based awards granted include stock options and restricted stock awards. We utilize the Black Scholes option pricing model to estimate the grant date fair value of stock options, which requires the input of highly subjective assumptions, including estimating stock price volatility and expected term. Historical volatility of our stock price was used while the expected term for our options was estimated based on historical option exercise behavior and post-vesting forfeitures of options, and the contractual term, the vesting period and the expected term of the outstanding options. Further, we apply an expected forfeiture rate in determining the amount of share-based compensation. We use historical forfeitures to estimate the rate of future forfeitures. Changes in these inputs and assumptions can materially affect the measure of estimated fair value of our stock compensation. The cost of restricted stock awards is determined using the fair value of our common stock on the date of grant.

We recognize the compensation costs net of an estimated forfeiture rate over the requisite service period of the options award, which is generally the vesting term of four years. Compensation expense for restricted stock awards is recognized over the vesting period, which is generally one, three or four years. Stock-based compensation expense is recorded in cost of revenue, research and development, and selling, general and administrative expenses.

Income Taxes

We account for income taxes in accordance with ASC Topic 740, Income Taxes ("ASC 740"), which requires that deferred tax assets and liabilities be recognized using enacted tax rates for the effect of temporary differences between the book and tax bases of recorded assets and liabilities. ASC 740 also requires that deferred tax assets be reduced by a valuation allowance if it is more likely than not that a portion of the deferred tax asset will not be realized. Our deferred tax assets have been reduced to zero by valuation allowance.

We provide for income taxes based upon the geographic composition of worldwide earnings and tax regulations governing each region, particularly China. The calculation of tax liabilities involves significant judgment in estimating the impact of uncertainties in the application of complex tax laws, particularly in foreign countries such as China.

See Note 14—"Income Taxes" in the notes to condensed consolidated financial statements for additional information.

Results of Operations

Revenue

	Three Months Ended September 30, Increase					Nine Months Ended September 30, Increase						
	2018	2017	(Decreas	se)% Chan	ge	2018	2017	(Decrease)	% Change			
Product									_			
Type:	(\$ in thousa	ands)				(\$ in thousa	ands)					
Substrates	\$ 22,802	\$ 22,377	\$ 425	1.9	%	\$ 63,769	\$ 58,095	\$ 5,674	9.8	%		
Raw												
Materials												
and Others	5,824	5,791	33	0.6	%	16,396	14,246	2,150	15.1	%		
Total												
revenue	\$ 28,626	\$ 28,168	\$ 458	1.6	%	\$ 80,165	\$ 72,341	\$ 7,824	10.8	%		

Revenue increased \$0.5 million, or 1.6%, to \$28.6 million for the three months ended September 30, 2018 from \$28.2 million for the three months ended September 30, 2017. The revenue increase for the three months ended September 30, 2018 as compared to the same period in 2017 was primarily the result of a higher demand for our InP substrates, primarily due to increased demand in the passive optical network (PON) and the silicon photonics market. The increase in InP substrate sales resulted from a higher number of overall units sold while average selling prices remained either flat or decreased slightly. Raw materials sales remained virtually flat at \$5.8 million for the three months ended September 30, 2018 and for the three months ended September 30, 2017.

Revenue increased \$7.8 million, or 10.8%, to \$80.2 million for the nine months ended September 30, 2018 from \$72.3 million for the nine months ended September 30, 2017. The revenue increase for the nine months ended September 30, 2018 as compared to the same period in 2017 was primarily the result of higher demand for InP and Ge substrate wafers, as well as our semi-conducting GaAs wafers. Raw material sales increased 15% in the nine months ended September 30, 2018 as compared to the same period in 2017. The increase in our substrate sales resulted from a higher number of overall units sold while average selling prices remained either flat or decreased slightly. Our InP substrate revenue increased in the nine months ended September 30, 2018 as compared to the same period in 2017 primarily due to increased demand for the PON market and the silicon photonics market while our Ge substrate revenue increased primarily due to more planned satellite launches in 2018. Stronger raw materials sales in the nine months ended September 30, 2018 as compared to the same period in 2017 resulted primarily from a higher number of pBN crucibles sold and an increase in the average selling price of pBN crucibles. Additionally, the average selling price of purified gallium (greater than 4N purity) stabilized as demand increased and the market was less oversupplied, which contributed to the stronger performance of our raw materials sales.

Revenue by Geographic Region

	Three Mo Septembe				Increase			
	2018 2017				(Decrease)	% Change		
	(\$ in thou	sand	ls)					
China	\$ 10,268		\$ 7,203		\$ 3,065	42.6	%	
% of total revenue	36	%	26	%				
Taiwan	6,116		5,986		130	2.2	%	
% of total revenue	21	%	21	%				
Europe (primarily Germany)	4,879		6,192		(1,313)	(21.2)	%	
% of total revenue	17	%	22	%				
North America (primarily the United States)	2,967		2,159		808	37.4	%	
% of total revenue	11	%	8	%				
Asia Pacific (excluding China, Taiwan and Japan)	2,334		2,934		(600)	(20.4)	%	
% of total revenue	8	%	10	%				
Japan	2,062		3,694		(1,632)	(44.2)	%	
% of total revenue	7	%	13	%				
Total revenue	\$ 28,626		\$ 28,168		\$ 458	1.6	%	

Revenue from customers in China increased by 42.6% in the three months ended September 30, 2018, primarily due to an increase of \$2.2 million, or 55%, from wafer substrate sales and an increase of \$0.9 million, or 27%, from raw materials and others sales. Except for Ge substrate sales, which remained flat for the three months ended September 30, 2018, sales of each of GaAs and InP wafer substrates in China increased in the three months ended September 30, 2018 as compared to the same period in 2017. The growth of Ge substrate sales in China that we experienced in 2016 and 2017 continued into early 2018, but began to slow down as the demand of the satellite solar cell market remained flat in the three months ended September 30, 2018. Revenue from customers in North America increased by 37.4% in the three months ended September 30, 2018, primarily due to strong demand for GaAs substrates used in wireless and solar panel applications. Revenue from customers in Europe decreased by 21.2% due to a decrease in wafer substrate and raw material sales. Revenue from Japan, Taiwan and the other Asian Pacific countries, in aggregate, decreased by \$2.1 million in the three months ended September 30, 2018 due to a decrease in wafer substrate and raw material sales.

	Nine Month September 3	Increase			
	2018 2017		(Decrease)	% Change	
	(\$ in thousan	nds)			
China	\$ 26,271	\$ 17,949	\$ 8,322	46.4 %	
% of total revenue	33 %	6 25 %			
Europe (primarily Germany)	17,957	17,638	319	1.8 %	

Edgar Filing: AXT INC - Form 10-Q

% of total revenue	22	%	24	%			
Taiwan	15,445		13,499		1,946	14.4	%
% of total revenue	19	%	19	%			
North America (primarily the United States)	7,052		5,909		1,143	19.3	%
% of total revenue	9	%	8	%			
Japan	7,041		9,696		(2,655)	(27.4)	%
% of total revenue	9	%	13	%			
Asia Pacific (excluding China, Taiwan and Japan)	6,399		7,650		(1,251)	(16.4)	%
% of total revenue	8	%	11	%			
Total revenue	\$ 80,165		\$ 72,341		\$ 7,824	10.8	%

Revenue from customers in China increased by 46.4% in the nine months ended September 30, 2018, primarily due to an increase of \$6.1 million, or 59%, from wafer substrate sales and an increase of \$2.2 million, or 29%, from raw materials. Revenue from customers in Taiwan increased by 14.4% in the nine months ended September 30, 2018, primarily due to an increase of \$1.9 million from wafer substrate sales. Revenue from customers in North America

Table of Contents

increased by 19.3% in the nine months ended September 30, 2018, primarily due to stronger demand in GaAs wafer substrates as compared to the same period in 2017. Revenue from customers in Europe increased by 1.8% in the nine months ended September 30, 2018 primarily due to stronger demand in GaAs and InP wafer substrate sales as compared to the same period in 2017. However, the combined revenue from other Asian countries and Japan decreased \$3.9 million for the nine months ended September 30, 2018 to \$13.4 million from \$17.3 million for the nine months ended September 30, 2018 as compared to the same period in 2017 was primarily due to a decrease in our substrate product sales in these regions, which was partially offset by an increase in raw materials sales in these regions in the nine months ended September 30, 2018.

Gross Margin

	Three M Septemb				Increase			Nine Mos September			Increase		
	2018		2017		(Decrease)	% Change		2018		2017	(Decrease)	% Change	
	(\$ in tho	usan	ds)			_		(\$ in thou	ısano	ds)		_	
Gross profit Gross	\$ 10,614	4	\$ 11,13	33	\$ (519)	(4.7)	%	\$ 31,197		\$ 24,677	\$ 6,520	26.4	%
Margin %	37.1	%	39.5	%				38.9	%	34.1 %			

Gross profit decreased \$0.5 million, or 4.7%, to \$10.6 million for the three months ended September 30, 2018 from \$11.1 million for the three months ended September 30, 2017. Although revenue increased by \$0.5 million, gross margin decreased primarily due to higher fixed overhead charges, higher priced raw materials and lower average selling prices for the three months ended September 30, 2018 as compared to the same period in 2017.

Gross profit increased \$6.5 million, or 26.4%, to \$31.2 million for the nine months ended September 30, 2018 from \$24.7 million for the nine months ended September 30, 2017. Gross profit increased primarily due to favorable product mix, overall improvements in yield and manufacturing efficiencies and higher production volume for the nine months ended September 30, 2018 as compared to the same period in 2017.

Selling, General and Administrative Expenses

Nine Months Ended

Three Months Ended

	September 30,		Increase	Sep	tember 30), Inc	Increase		
	2018	2017	(Decrease)	% Change	201	8 2017	7 (De	crease% (Change
	(\$ in thousan	nds)			(\$ i	n thousan	ds)		
Selling, general and									
administrative expenses	\$ 4,615	\$ 4,484	\$ 131	2.9	% \$	13,82\$4	12,219	\$1,605	13%
% of total revenue	16.1 %	15.9 %				17. ½	16. %		

Selling, general and administrative expenses increased \$0.1 million, or 2.9%, to \$4.6 million for the three months ended September 30, 2018 from \$4.5 million for the three months ended September 30, 2017. The higher selling, general and administrative expenses were primarily from higher personnel-related costs from hiring a new direct sales professional in Europe and higher travel expenses related to traveling to our new manufacturing sites, which were partially offset by lower professional service fees and lower sales commission expense resulting from the termination of our European sales representative.

Selling, general and administrative expenses increased \$1.6 million, or 13.1%, to \$13.8 million for the nine months ended September 30, 2018 from \$12.2 million for the nine months ended September 30, 2017. The higher selling, general and administrative expenses incurred in the nine months ended September 30, 2018 as compared to the same period of 2017 were primarily from higher personnel-related costs from hiring a new direct sales professional in Europe and higher travel expenses related to traveling to our new manufacturing sites which were partially offset by lower professional service fees, lower sales commission resulting from the termination of our European sales representatives in Europe and the absence of expenses incurred as a result of business interruption caused by the electrical fire in our Beijing facility on March 15, 2017.

Research and Development

	Three Months Ended							Nine M					
	September 30,			Increase			September 30,			Increase			
	2018	2	017		(Decreas	se)% Change		2018		2017	(Decrease)	% Change	
(\$ in thousands)								(\$ in thousands)					
Research and	l												
development	\$ 1,668	\$	1,410)	\$ 258	18.3	%	\$ 4,588	3	\$ 3,553	\$ 1,035	29.1	%
% of total													
revenue	5.8	%	5.0	%				5.7	%	4.9 %			

Research and development expenses increased \$0.3 million, or 18.3%, to \$1.7 million for the three months ended September 30, 2018 from \$1.4 million for the three months ended September 30, 2017. Research and development expenses increased \$1.0 million, or 29.1%, to \$4.6 million for the nine months ended September 30, 2018 from \$3.6 million for the nine months ended September 30, 2017. The increase in research and development expenses for the three and nine months ended September 30, 2018 was primarily due to the increased use of raw materials for product development programs at two of our consolidated subsidiaries and higher personnel-related costs.

Interest Income, Net

	Three Months Ended September 30, Increase							ine Month nded eptember 3	,	Increase			
	2018 (\$ in thous	2017 (ands)	(D	ecrease)	% Change)18 in thousa	017 ls)	(D	ecrease)	% Change	;
Interest income, net % of total	\$ 133	\$ 122	\$	11	9.0	%	\$	414	\$ 334	\$	80	24.0	%
revenue	0.5 %	0.4 %						0.5 %	0.5 %				

Interest income, net remained unchanged for the three months ended September 30, 2018 as compared to the same period in 2017. Interest income, net increased for the nine months ended September 30, 2018 as compared to the same period in 2017 primarily due to higher market interest rates.

Equity in Earnings (Loss) of Unconsolidated Joint Ventures

	Th	ree Mo	nths								
	Ended						Nine Montl	hs Ended			
	September 30,		r 30,	Equity in Earnings			September	30,	Equity in Earnings		
	201	18	2017	Change	% Change		2018	2017	Change	% Change	
	(\$ in thousands)						(\$ in thousa	ands)			
Equity in											
earnings (loss)											
of											
unconsolidated											
joint ventures	\$	6	\$ (266)	\$ 272	102.3	%	\$ (21)	\$ (1,387)	\$ 1,366	98.5	%
% of total											
revenue	(0.0 %	(0.9) %				(0.0) %	(1.9) %			

Equity in earnings (loss) of unconsolidated joint ventures is the aggregate net income (loss) from our seven minority-owned joint ventures that are not consolidated. Equity in earnings of unconsolidated joint ventures increased \$272,000 to earnings of \$6,000 for the three months ended September 30, 2018 from a loss of \$266,000 for the three months ended September 30, 2017 as our unconsolidated joint ventures reported better performance in the three months ended in September 30, 2018 as compared to the same period of 2017. The improvement is the result of price increases for raw materials. There were no impairment charges in the three months ended September 30, 2018 and September 30, 2017.

Equity in loss of unconsolidated joint ventures decreased \$1.4 million to a loss of \$21,000 for the nine months ended September 30, 2018 from a loss of \$1.4 million for the nine months ended September 30, 2017 as a result of the absence of a \$313,000 impairment charge for one of the joint ventures that produces gallium in the nine months ended September 30, 2017, better performance of our unconsolidated joint ventures and price increases for raw materials in the nine months ended in September 30, 2018 as compared to the same period of 2017. There were no impairment charges in the nine months ended September 30, 2018. Equity in loss of unconsolidated joint ventures for the nine months ended

Table of Contents

September 30, 2017 includes an impairment charge of \$313,000 for one of the joint ventures that produces gallium. During the first quarter of 2017, management determined it is unlikely that this company will recover from the difficult pricing environment and we wrote the investment down to zero.

Other Expense, Net

	Three Mo	nths										
	Ended				Ni	Nine Months Ended						
	Septembe	r 30,	Other Income			ptember 3	0,	Other Income				
	2018	2017	Change	% Change	20	18	2017	Change	% Change			
	(\$ in thou	sands)				in thousan	nds)					
Other income												
(expense), net	\$ 87	\$ (349)	\$ 436	124.9	% \$	(179)	\$ (403)	\$ 224	55.6	%		
% of total												
revenue	0.3 %	(1.2) %			((0.2) %	(0.6) %					

Other income, net increased \$436,000 to an income of \$87,000 for the three months ended September 30, 2018 from a loss of \$349,000 for the three months ended September 30, 2017. Other income, net increased primarily due to a higher foreign exchange gain in the three months ended September 30, 2018 as compared to the same period in 2017.

Other expense, net decreased \$224,000 to a loss of \$179,000 for the nine months ended September 30, 2018 from a loss of \$403,000. Other expense, net decreased primarily due to a lower foreign exchange loss for the nine months ended September 30, 2018 as compared to the same period in 2017.

Provision for Income Taxes

	Three M Ended		I			Nine Months Ended				
	Septemb	•	Increase	et et		September	•	Increase	01 CI	
	2018	2017	(Decrease)	% Chang	ge	2018	2017	(Decrease)	% Change	
	(\$ in tho	usands)				(\$ in thous	sands)			
Provision										
for income										
taxes	\$ 410	\$ 181	\$ 229	126.5	%	\$ 1,111	\$ 661	\$ 450	68.1	%

% of total

revenue 1.4 % 0.6 % 1.4 % 0.9 %

Provision for income taxes for the three and nine months ended September 30, 2018 was \$410,000 and \$1.1 million, respectively, which was mostly related to higher profits in our wholly-owned China subsidiaries and our three consolidated joint venture companies in China. No income taxes or benefits have been provided for our U.S. operations as the income in the U.S. had been fully offset by utilization of federal and state net operating loss carryforwards. Additionally, there is uncertainty of generating future profit in the U.S., which has resulted in our deferred tax assets being fully reserved. Our estimated tax rate can vary greatly from year to year because of the change or benefit in the mix of taxable income between our U.S. and China-based operations.

Due to our uncertainty regarding our future profitability in the U.S., we recorded a full valuation allowance against our net deferred tax assets of \$22 million in 2017, \$68 million in 2016 and \$66 million in 2015.

Net (Income) Loss Attributable to Noncontrolling Interests

	Three Months Ended September 30,		Net income attributable to Noncontrolling interests			Nine Months Ended September 30,		Net income attributable to Noncontrolling interests		
	2018	2017	Increa	se Change		2018	2017	Increase	% Change	
	(\$ in thousands)				(\$ in thousan	ds)				
Net (income) loss attributable to noncontrolling										
interests % of total revenue	\$ (208) (0.7) %	\$ (146) (0.5) %	\$ 62	42.5	%	\$ (1,173) (1.5) %	\$ 226 0.3 %	\$ 1,399	619.0	%

Table of Contents

The increase in noncontrolling interests' share of income for the three months ended September 30, 2018 as compared to the same period in 2017 was due to higher profitability from two of our three consolidated subsidiaries in China, which was partially offset with lower profitability from our other consolidated subsidiary in China.

The increase in noncontrolling interests' share of income for the nine months ended September 30, 2018 as compared to the same period in 2017 was due to higher profitability from all three of our consolidated subsidiaries in China.

Liquidity and Capital Resources

We consider cash and cash equivalents, short-term investments and long-term investments as liquid and available for use within two years in our current operations. Short-term investments and long-term investments are comprised of U.S. government securities, certificates of deposit and investment-grade corporate notes and bonds.

As of September 30, 2018, our principal source of liquidity was \$41.9 million, which consisted of cash and cash equivalents of \$18.0 million, short-term investments of \$21.9 million and long-term investments of \$1.9 million. In the nine months ended September 30, 2018, cash and cash equivalents decreased by \$26.3 million and short-term and long-term investments decreased by \$8.8 million. The decrease in cash and cash equivalents of \$26.3 million in the nine months ended September 30, 2018 was primarily due to net cash used in investing activities of \$25.6 million, net cash used in operating activities of \$0.2 million and the effect of exchange rate changes of \$0.6 million partially offset by net cash provided by financing activities of \$0.1 million. As of September 30, 2018, we and our consolidated joint ventures held approximately \$11.9 million in cash and investments in foreign bank accounts. This consists of \$4.6 million held by our wholly owned subsidiaries in China and \$7.3 million held by our three partially-owned consolidated subsidiaries in China.

As of September 30, 2017, our principal source of liquidity was \$78.3 million, which consisted of cash and cash equivalents of \$48.1 million, short-term investments of \$20.5 million and long-term investments of \$9.7 million. In the nine months ended September 30, 2017, cash and cash equivalents increased by \$11.9 million and short-term and long-term investments increased by \$12.6 million. The increase in cash and cash equivalents of \$11.9 million in the nine months ended September 30, 2017 was primarily due to net cash provided by operating activities of \$8.0 million, net cash provided by financing activities of \$32.9 million, primarily due to the net proceeds of \$31.9 million received from the public offering of 5,307,692 shares of our common stock in March 2017 and proceeds of \$1.5 million from the exercise of common stock options partially offset by the net dividends paid by our joint ventures of \$0.5 million, which were partially offset by net cash used in investing activities of \$29.2 million. As of September 30, 2017, we and our consolidated joint ventures held approximately \$19.0 million in cash and investments in foreign bank accounts. This consists of \$11.2 million held by our wholly-owned subsidiaries in China and \$7.8 million held by our three partially-owned consolidated subsidiaries in China.

Net cash used in operating activities of \$0.2 million for the nine months ended September 30, 2018 was primarily comprised of a net change of \$17.1 million in operating assets and liabilities, primarily due to the net increase from inventories of \$14.6 million, which were partially offset by net income of \$11.9 million, adjusted for non-cash items of depreciation and amortization of \$3.4 million, stock-based compensation of \$1.4 million and amortization of marketable securities of \$0.1 million.

Net cash provided by operating activities of \$8.0 million for the nine months ended September 30, 2017 was primarily comprised of net income of \$6.8 million, adjusted for non-cash items of depreciation and amortization of \$3.4 million, loss on equity method investments of \$1.1 million, stock-based compensation of \$1.0 million, impairment charge on equity investee of \$0.3 million, which were partially offset by a net change of \$4.6 million in operating assets and liabilities.

Net cash used in investing activities of \$25.6 million for the nine months ended September 30, 2018 was primarily from the purchase of property, plant and equipment of \$34.3 million and the purchase of marketable investment securities totaling \$9.9 million, which were partially offset by proceeds from maturities and sales of available-for-sale securities of \$18.6 million.

Net cash used in investing activities of \$29.2 million for the nine months ended September 30, 2017 was primarily from the purchase of marketable investment securities totaling \$26.1 million and the purchase of property, plant and equipment of \$16.6 million, which were partially offset by proceeds from maturities and sales of available-for-sale securities of \$13.3 million.

Net cash provided by financing activities was \$0.1 million for the nine months ended September 30, 2018, which consisted of net proceeds of \$264,000 on the issuance of common stock pursuant to stock option exercises and net proceeds of short-term loans of \$291,000, which were partially offset by the purchase of subsidiary shares from noncontrolling interest of \$415,000.

Net cash provided by financing activities was \$32.9 million for the nine months ended September 30, 2017, which mainly consisted of \$31.9 million net proceeds from the issuance of 5,307,692 shares of common stock as a result of our March 2017 stock offering and net proceeds of \$1.5 million on the issuance of common stock pursuant to stock option exercises, which were partially offset by net dividends paid by our joint ventures of \$0.5 million.

On October 27, 2014, our Board of Directors approved a stock repurchase program pursuant to which we may repurchase up to \$5.0 million of our outstanding common stock. These repurchases could be made from time to time in the open market and could be funded from our existing cash balances and cash generated from operations. During 2015, we repurchased approximately 908,000 shares at an average price of \$2.52 per share for a total purchase price of approximately \$2.3 million under the stock repurchase program. No shares were repurchased during 2016 under this program. During nine months ended September 30, 2018, we did not repurchase any shares under the approved stock repurchase program. As of September 30, 2018, approximately \$2.7 million remained available for future repurchases under this program. Currently, we do not plan to repurchase additional shares.

Dividends accrue on our outstanding Series A preferred stock, and are payable as and when declared by our board of directors. We have never declared or paid any dividends on the Series A preferred stock. By the terms of the Series A preferred stock, so long as any shares of Series A preferred stock are outstanding, neither the Company nor any subsidiary of the Company shall redeem, repurchase or otherwise acquire any shares of common stock, unless all accrued dividends on the Series A preferred stock have been paid. During 2013 and 2015, we repurchased shares of our outstanding common stock. As of December 31, 2015, the Series A preferred stock had cumulative dividends of \$2.9 million and we include such cumulative dividends in "Accrued liabilities" in our condensed consolidated balance sheets. If we are required to pay the cumulative dividends on the Series A preferred stock, our cash and cash equivalents would be reduced. We account for the cumulative year to date dividends on the Series A preferred stock when calculating our earnings per share.

The China central government is working with the Beijing city government to design a master development plan of the area where our manufacturing facility is located, which will result in the relocation of many of the manufacturing

companies in our district. We are required to relocate our gallium arsenide production line. We are cooperating with the government and, in accordance with our relocation plan, are relocating our gallium arsenide production line as well as our germanium production line. We will consider relocating our indium phosphide production subsequently. On September 12, 2017, we announced that we completed the purchase of a new manufacturing site in the city of Dingxing, China. The Dingxing site is approximately 18.75 acres and included three existing buildings, which comprise approximately 140,000 sq. feet of production space and 50,000 sq. feet designated for offices and dormitories. We believe that 3D-sensing VCELs will require additional gallium arsenide capacity and we are constructing a fourth building at this site. In addition, we have acquired a second new site in city of Kazuo, located in the province in Liaoning near the Inner Mongolia Autonomous Region, which will initially be used for poly synthesis and ingot growth for gallium arsenide and germanium as well as possible expansion of indium phosphide ingot growth. We do not yet have comprehensive construction bids for further modifications to the existing buildings or the construction of new buildings or third party estimates for the complete relocation costs, but we believe these costs will be in the range of \$40 million to \$50 million, which includes the amount we have already paid for the purchase of our new manufacturing facilities and will extend into 2019. However, such costs could be higher than our current estimates.

Table of Contents

One of our consolidated joint venture companies, JinMei, is in the process of relocating its manufacturing operation to Kazuo, very near our new site in Kazuo, and the estimated cost for the relocation is in the range of \$2 million to \$4 million. Another of our consolidated joint venture companies is also relocating its manufacturing operations to Kazuo and the estimated cost for the relocation is in the range of \$3 million to \$4 million.

In September 2018, Tongmei entered into a credit facility with ICBC in China with a \$2.9 million line of credit at an annual interest rate of approximately 0.04% over the current Loan Prime Rate by published by ICBC. Accrued interest is calculated and paid monthly. The annual interest rate was approximately 4.4% as of September 30, 2018. This credit line is secured by Tongmei's land-use right and all of its buildings located at its facility in Beijing. The primary intended use of the credit facility is for general purposes, which may include working capital, capital expenditures and other corporate expenses.

On September 30, 2018, we borrowed \$291,000 against this credit line. The repayment of the full amount is due in September 2019. As of September 30, 2018, \$291,000 was included in "Bank loan" in our condensed consolidated balance sheets.

We believe that we have adequate cash and investments to meet our operating needs over the next twelve months. If our sales decrease, however, our ability to generate cash from operations will be adversely affected which could adversely affect our future liquidity, require us to use cash at a more rapid rate than expected, and require us to seek additional capital.

On October 24, 2016, we filed with the SEC a registration statement on Form S-3, pursuant to which we may offer up to \$60 million of common stock, preferred stock, depositary shares, warrants, debt securities and/or units in one or more offerings and in any combination. On November 4, 2016, the SEC declared the registration statement effective. A prospectus supplement, which we will provide each time we offer securities, will describe the specific amounts, prices and terms of the securities we determine to offer.

On March 2, 2017, we filed with the SEC a final prospectus supplement, pursuant to which we offered and sold 5,307,692 shares of our common stock. The net proceeds are being used for the relocation of our gallium arsenide production line, for equipment capital expenditures, working capital for accounts receivable and inventory, possible acquisitions of complementary products, technologies or businesses and other general purposes.

Cash from operations could be affected by various risks and uncertainties, including, but not limited to those set forth below under Item 1A "Risk Factors".

Contractual Obligations and Operating Leases

We lease certain office space, warehouse facilities and equipment under long-term operating leases expiring at various dates through April 2023. The majority of our lease obligations relates to our lease agreement for the facility in Fremont, California with approximately 19,467 square feet.

We entered into a royalty agreement with a competitor effective December 3, 2010 with a term of eight years, terminating December 31, 2018. We and our related companies are granted a worldwide, nonexclusive, royalty bearing, irrevocable license to certain patents for the term of the agreement. We shall pay up to \$7.0 million of royalty payments over eight years that began in 2011 based on future royalty bearing sales. This agreement contains a clause that allows us to claim credit, starting in 2013, in the event that the royalty bearing sales for the year is lower than a pre-determined amount set forth in this agreement.

Outstanding contractual obligations as of September 30, 2018 are summarized as follows (in thousands):

	Payment	s due	by period				
				1-3	4-5	Mo	re than
Contractual Obligations	Total	Less than 1 year		years	years	5 years	
Operating leases	\$ 452	\$	193	\$ 233	\$ 26	\$	
Royalty agreement	144		144	_			
Total	\$ 596	\$	337	\$ 233	\$ 26	\$	

Purchase orders or contracts for the purchase of certain goods and services are not included in the preceding table. We cannot determine the aggregate amount of such purchase orders that represent contractual obligations because purchase orders may represent authorizations to purchase rather than binding agreements. For the purposes of this table, contractual obligations for purchase of goods or services are defined as agreements that are enforceable and legally binding and that specify all significant terms, including fixed or minimum quantities to be purchased; fixed, minimum, or variable price provisions; and the approximate timing of the transaction. Our purchase orders are based on our current needs and are fulfilled by our vendors within short time horizons. We also enter into contracts for outsourced services; however, the obligations under these contracts were not significant and the contracts generally contain clauses allowing for cancellation without significant penalty. Contractual obligations that are contingent upon the achievement of certain milestones are not included in the table above.

Land Purchase and Investment Agreement

We are in the process of relocating our gallium arsenide production line to Dingxing, China. In addition to a land rights and building purchase agreement that we entered into with a private real estate development company to acquire our new manufacturing facility, we also entered into a cooperation agreement with the Dingxing local government. In addition to pledging its full support and cooperation, the Dingxing local government will issue certain credits or rebates to us as we achieve certain milestones. We, in turn, agreed to hire local workers over time, pay taxes when due and eventually demonstrate a total investment of approximately \$90 million in value, assets and capital. The investment will include cash paid for the land and buildings, cash on deposit in our name at local banks, the gross value of new and used equipment (including future equipment that might be used for indium phosphide and germanium substrates production), the deemed value for our customer list or the end user of our substrates (for example, the end users of 3-D sensing VCSELs), a deemed value for employment of local citizens, a deemed value for our proprietary process technology, other intellectual property, other intangibles and additional items of value. There is no timeline or deadline by which this must be accomplished, rather it is a good faith covenant entered into between AXT and the Dingxing local government. Further, there is no specific penalty contemplated if either party breaches the agreement. However the agreement does state that each party has a right to seek from the other party compensation for losses. Under certain conditions, the Dingxing local government may purchase the land and building at the appraised value. We believe that such cooperation agreements are normal, customary and usual in China and that the future valuation is flexible. We have a similar agreement with the city of Kazuo, China, although on a smaller scale.

Edgar imig. 7001 100 Q
The total investment targeted by AXT in Kazuo is approximately \$15 million in value, assets and capital.
Off-Balance Sheet Arrangements
As of September 30, 2018, we did not have any off-balance sheet financing arrangements and have never established any special purpose entities as defined under SEC Regulation S-K Item 303(a)(4)(ii).
Recent Accounting Pronouncements
For a description of recent accounting pronouncements, including the expected dates of adoption and estimated effects, if any, on our condensed consolidated financial statements, please see "Note 17 - Recent Accounting Pronouncements" in the Notes to Condensed Consolidated Financial Statements of this Form 10-Q.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Foreign Currency Risk

A significant portion of our business is conducted in currencies other than the U.S. dollar. Foreign exchange losses have had a material adverse effect on our operating results and cash flows in the past and could have a material adverse effect on our operating results and cash flows in the future. If we do not effectively manage the risks associated with this currency risk, our revenue, cash flows and financial condition could be adversely affected. Although during 2016 and 2015, we recorded a foreign exchange gain of \$232,000 and \$717,000, respectively, during 2017 we recorded a net foreign exchange loss of \$602,000, included as part of other (expense) income, net in our consolidated statements of operation. We incur foreign currency transaction exchange gains and losses due to operations in general. In the future we may experience foreign exchange losses on our non-functional currency denominated receivables and payables to the extent that we have not mitigated our exposure. Foreign exchange losses could have a materially adverse effect on our operating results and cash flows.

Our product sales to Japanese customers are typically invoiced in Japanese yen. As such we have foreign exchange exposure on our accounts receivable and on any Japanese yen denominated cash deposits. In 2014 and the first half of 2015, the Japanese yen depreciated against the dollar. The major portion of our 2014 exchange loss is attributable to the Japanese yen's movement.

To partially protect us against fluctuations in foreign currency resulting from accounts receivable in Japanese yen, starting in 2015, we instituted a foreign currency hedging program. We place short term hedges that are intended to offset the potential cash exposure related to fluctuations in the exchange rate between the United States dollar and Japanese yen. We measure the fair value of these hedges at each month end and quarter end using current exchange rates and in accordance with generally accepted accounting principles. At quarter end and year end any foreign currency hedges not settled are netted on the condensed consolidated balance sheet and consolidated balance sheet, respectively, and classified as Level 3 assets and liabilities. As of September 30, 2018, the net change in fair value from the placement of the hedge to settlement at each month end during the quarter had a de minimis impact to the consolidated results.

The functional currency for our foreign operations is the renminbi, the local currency of China, and in the future we may establish short term hedges covering renminbi. Most of our operations are conducted in China and most of our costs are incurred in Chinese renminbi, which subjects us to fluctuations in the exchange rates between the U.S. dollar and the Chinese renminbi. We incur transaction gains or losses resulting from consolidation of expenses incurred in local currencies for our Chinese subsidiaries, as well as in translation of the assets and liabilities at each balance sheet date. Our financial results could be adversely affected by factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets, including the revaluation by China of the renminbi, and any future adjustments that China may make to its currency such as any move it might make to a managed float system with opportunistic interventions. We may also experience foreign exchange losses on our non-functional currency

denominated receivables and payables.

We currently are using a hedging program to minimize the effects of currency fluctuations relating to the Japanese yen. While we may apply this program to other currencies, such as the Chinese renminbi, our hedging position is partial and may not exist at all in the future. It may not succeed in minimizing our foreign currency fluctuation risks. Our primary objective in holding these instruments is to reduce the volatility of earnings and cash flows associated with changes in foreign currency. The program is not designated for trading or speculative purposes. The company may choose not to hedge certain foreign exchange exposures for a variety of reasons, including but not limited to accounting considerations and the prohibitive economic cost of hedging particular exposures. However, even with our hedging program, we still experience losses on foreign exchange from time to time.

Interest Rate Risk

Cash and cash equivalents earning interest and certain variable rate debt instruments are subject to interest rate fluctuations. The following table sets forth the probable impact of a 10% change in interest rates (in thousands):

				Proforma 10%	Proforma 10%
	Balance as of	Current	Projected Annual	Interest Rate	Interest Rate
	September 30,	Interest	Interest	Decline	Increase
Instrument	2018	Rate	Income	Income	Income
Cash and cash equivalents	\$ 18,035	0.44 %	\$ 79	\$ 71	\$ 87
Investments in marketable					
debt	23,816	2.41 %	574	517	631
			\$ 653	\$ 588	\$ 718

The primary objective of our investment activities is to preserve principal while maximizing income without significantly increasing risk. Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, short-term investments, and trade accounts receivable. We invest primarily in money market accounts, certificates of deposits, corporate bonds and notes, and government securities. We are exposed to credit risks in the event of default by the issuers to the extent of the amount recorded on the condensed consolidated balance sheets. These securities are generally classified as available-for-sale and consequently are recorded on the balance sheet at fair value with unrealized gains or losses reported as a separate component of accumulated other comprehensive income, net of estimated tax. Our cash, cash equivalents and short-term investments and long-term investments are in high-quality instruments placed with major banks and financial institutions and commercial paper. We have no investments in auction rate securities.

Credit Risk

We perform ongoing credit evaluations of our customers' financial condition, and limit the amount of credit extended when deemed necessary, but generally do not require collateral. The credit risk in our accounts receivable is mitigated by our credit evaluation process and the broad dispersion of sales transactions. Three customers accounted for 15%, 14% and 11% of our accounts receivable balance as of September 30, 2018, and one customer accounted for 12% of our accounts receivable balance as of December 31, 2017.

Equity Risk

As part of our supply chain strategy, we maintain minority investments in privately-held companies located in China either invested directly by us and our wholly-own subsidiary or indirectly through our three consolidated joint venture companies. These minority investments are reviewed for other than temporary declines in value on a quarterly basis. These investments are classified as other assets in the condensed consolidated balance sheets and accounted for under either the equity or cost method, depending on whether we have the ability to exercise significant influence over their operations or financial decisions. We monitor our investments for impairment and record reductions in carrying value when events or changes in circumstances indicate that the carrying value may not be recoverable. Reasons for other than temporary declines in value include whether the related company would have insufficient cash flow to operate for the next twelve months, significant changes in the operating performance and changes in market conditions. As of September 30, 2018 and December 31, 2017, we did not maintain any direct investments under the cost method, our direct three minority investments under the equity method totaled \$5.1 million and \$5.6 million, respectively, and our four indirect minority investments by our consolidated joint ventures totaled \$4.4 million and \$4.3 million, respectively. In aggregate, as of September 30, 2018 and December 31, 2017, the total of our direct and indirect investments in the seven companies under the equity method totaled \$9.5 million and \$9.8 million, respectively.

Table of Contents

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this quarterly report. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures as defined under Securities Exchange Act Rules 13a-15(e) and 15d-15(e) were effective at the reasonable assurance level to ensure that information required to be disclosed in our Securities Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the Securities and Exchange Commission and is accumulated and communicated to management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Our disclosure controls and procedures include components of our internal control over financial reporting. Management's assessment of the effectiveness of our internal control over financial reporting is expressed at the level of reasonable assurance because a control system, no matter how well designed and operated, can provide only reasonable assurance that the control system's objectives will be met.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting made in the three and nine months ended September 30, 2018 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

From time to time we may be involved in judicial or administrative proceedings concerning matters arising in the ordinary course of business. We do not expect that any of these matters, individually or in the aggregate, will have a material adverse effect on our business, financial condition, cash flows or results of operation.

Item 1A. Risk Factors

For ease of reference, we have divided these risks and uncertainties into the following general categories:

- I. Risks related to our general business;
- II. Risks related to international aspects of our business;
- III. Risks related to our financial results and capital structure;
- IV. Risks related to our intellectual property; and
- V. Risks related to compliance, environmental regulations and other legal matters.
- I. Risks Related to Our General Business

Silicon substrates (wafers) are significantly lower in cost compared to substrates made from specialty materials, and new silicon-based technologies could enable silicon based substrates to replace specialty material based substrates for certain applications.

Historically silicon wafers or substrates are less expensive than specialty material substrates, such as those that we produce. Electronic circuit designers will generally consider silicon first and only turn to alternative materials if silicon cannot provide the required functionality in terms of power consumption, speed, wave lengths or other specifications. Beginning in 2011, certain applications that had previously used GaAs substrates adopted a new silicon-based technology called silicon on insulator, or SOI. SOI technology uses a silicon-insulator-silicon layered substrate in place of conventional silicon substrates in semiconductor manufacturing. SOI substrates cost less than GaAs substrates and, although their performance is not as robust as GaAs substrates in terms of power consumption, heat generation and speed, they became acceptable in mobile phones and other applications that were previously dominated by GaAs substrates. The adoption of SOI resulted in decreased GaAs wafer demand, and decreased revenue. If SOI or similar technologies gain more widespread market acceptance, or are used in more applications, our sales of specialty material based substrates could be reduced and our business and operating results could be significantly and adversely affected.

Our gross margin has fluctuated historically and may decline due to several factors.

Our gross margin has fluctuated from period to period as a result of shifts in the cost of raw materials, shifts in product mix, hiring additional manufacturing employees at our new locations, tariffs imposed by the U.S. government, the introduction of new products, decreases in average selling prices for products, utilization of our manufacturing capacity, fluctuations in manufacturing yields and our ability to reduce product costs. These factors and other variables change from period to period and these fluctuations are expected to continue in the future.

In recent months, the prices of many of the raw materials that we use in our substrate manufacturing process have increased. Such price increases can increase our cost of goods sold and reduce our gross margin.

Further, we do not control the prices at which our subsidiaries and other joint venture companies sell their raw material products to third parties and we do not control their production process. However, because we consolidate the results of three of these companies with our own, any reduction in their gross margins could have a significant, adverse

Table of Contents

impact on our overall gross margins. One or more of our companies has in the past sold, and may in the future sell, raw materials at significantly reduced prices in order to gain volume sales or sales to new customers. In addition, at some points in the last three years, the market price of gallium dropped below our per unit inventory cost and we incurred an inventory write down under the lower of cost or net realizable value accounting rules. In this regard, in the first quarter of 2018 our consolidated raw gallium company incurred a \$295,000 charge. In such events, our gross margin is adversely impacted.

Underutilizing our manufacturing facilities may result in declines in our gross margins.

An important factor in our success is the extent to which we are able to utilize the available capacity in our manufacturing facilities. A number of factors and circumstances may reduce utilization rates, including periods of industry overcapacity, low levels of customer orders, operating inefficiencies, mechanical failures and disruption of operations due to expansion, power interruptions, fire, flood, other natural disasters or calamities or government-ordered mandatory factory shutdowns. Severe air pollution in Beijing can trigger mandatory factory shutdowns. For example, in the first quarter of 2018, over 300 manufacturing companies, including AXT, were intermittently shut down by the local government for a total of ten days from February 27 to March 31, due to severe air pollution. Further, we are increasing capacity by adding two new sites, which may reduce our utilization rate and increase our depreciation charges, at least until we de-commission part of our Beijing site. Because many portions of our manufacturing costs are relatively fixed, high utilization rates are critical to our gross margins and operating results. If we fail to achieve acceptable manufacturing volumes or experience product shipment delays, our results of operations will be negatively affected. During periods of decreased demand, we have underutilized our manufacturing lines. If we are unable to improve utilization levels at our facilities during periods of decreased demand and correctly manage capacity, the fixed expense levels will have an adverse effect on our business, financial condition and results of operations. For example, in the three months ended December 31, 2015, our revenue dropped to \$18.1 million and our gross margin was only 17.1%.

In 2013, we concluded that incoming orders were insufficient and that we were significantly underutilizing our factory capacity. As a result, in February 2014, we announced a restructuring plan with respect to our wholly-owned subsidiary, Beijing Tongmei Xtal Technology Co, Ltd., in order to better align manufacturing capacity with demand. Under the restructuring plan, we recorded a charge of approximately \$907,000 in the first quarter of 2014. In the second quarter of 2016, we restructured the operations of Beijing JiYa Semiconductor Material Co., Ltd., one of our partially owned consolidated subsidiaries, which resulted in a reduction in force of 28 positions that were no longer required to support production and operations.

If we receive fewer customer orders than forecasted or if our customers delay or cancel orders, we may not be able to reduce our manufacturing costs in the short-term and our gross margins would be negatively affected. In addition, lead times required by our customers are shrinking, which reduces our ability to forecast orders and properly balance our capacity utilization.

If we have low product yields, the shipment of our products may be delayed and our product cost and operating results may be adversely impacted.

A critical factor in our product cost is yield. Our products are manufactured using complex crystal growth and wafer processing technologies, and the number of usable wafer substrates we produce can fluctuate as a result of many factors, including:

- · poor control of furnace temperature and pressure;
- · impurities in the materials used;
- · contamination of the manufacturing environment;

- · quality control and inconsistency in quality levels;
- · lack of automation and inconsistent processing requiring manual manufacturing steps;

Table of Contents

- · substrate breakage during the manufacturing process; and
- · equipment failure, power outages or variations in the manufacturing process.

A current example where yield is of special concern is for our six-inch semi-conducting gallium arsenide substrates, which can be used for manufacturing opto-electronic devices in cell phones, enabling 3-D sensing. This application requires very low defect densities, also called etch pit densities, or EPD, and our yields will be lower than the yields achieved for the same substrate when it will be used in other applications. If we are unable to achieve the targeted quantity of low defect dens